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„Cha, s kamarádem už jsme to chtěli zmáčknout, ale ten chlap řek' né. 
A my to stejně zmáčkli. A schovali se v obří pneumatice. A tam už byl 
náš další kamarád!“  
Homer Jay Simpson 
Simpsonovi, série 9, epizoda 18  
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Abstract 
Protein-protein interactions are involved in various biological processes and detailed 
characterization of their structural basis by the means of structural biology is often 
instrumental for rigorous understanding of underlying molecular mechanisms. This 
information is important not only for fundamental biology but also plays an important role in 
search for sites amenable for therapeutic intervention. Nuclear magnetic resonance 
spectroscopy is alongside X-ray crystallography and single-particle cryo-electron microscopy 
one of the key high-resolution techniques in structural biology. Although its applicability to 
larger systems has a well-known physical limit, it offers unique capabilities in addressing 
highly dynamic or inherently heterogeneous systems.  
In this doctoral thesis, the solution-based NMR approach was used for detailed structural 
characterization of selected biologically important proteins and their complexes that provided 
important insights into their biological roles. In three distinct projects, I (i) studied the 
relationship between the structural effects of particular modifications in the insulin-like 
growth factor II (IGF-II) and their selectivity to the insulin axis receptors; (ii) the specific 
binding mechanism of the SH3 domain from the Crk-associated substrate (CAS); (iii) and the 
structural basis for the membrane recruitment of Phosphatidylinositol 4-kinase beta 
(PI4KIIIβ). For the structural studies of IGF-II analogues, I developed an efficient purification 
protocol, prepared a series of modified proteins with altered preference for the cognate 
receptors and structurally characterized the analogues that showed markedly reduced binding 
towards insulin receptor. The obtained structural information suggested a key role for the 
semi-flexible C-domain from IGF-II in receptor binding specificity. In the project focused on 
how the CAS SH3 domain recognizes its ligands, I solved the structures of the free CAS SH3 
domain and in complex with two polyproline peptides motifs derived from either tyrosine 
phosphatase PTP-PEST or cytoskeletal protein Vinculin. The structural data shed the light on 
the detailed CAS SH3 binding mechanism, suggested that the CAS SH3 ligand binding is 
negatively regulated by a Src-mediated phosphorylation and led to identification of the two 
novel CAS cellular binding partners. In the search for the determinants of the PI4KIIIβ 
membrane targeting, I determined the structure of the complex formed between the N-
terminal region of PI4KIIIβ kinase and PolyQ domain of ACBD3 that revealed the detailed 
mechanism underlying the PI4KIIIβ membrane recruitment. 
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Abstrakt 
Protein-proteinové interakce se podílejí na celé řadě biologických procesů. Podrobná 
charakterizace jejich strukturní podstaty je důležitým nástrojem k pochopení s nimi spojených 
základních molekulárních mechanismů. Získané informace jsou důležité nejen pro biologii, 
ale také hrají důležitou roli při hledání míst vhodných pro terapeutickou intervenci. Ve 
strukturní biologii je nukleární magnetická rezonanční spektroskopie (NMR) spolu s 
rentgenovou krystalografií a jednočásticovou kryo-elektronovou mikroskopií jednou z 
klíčových technik s vysokým rozlišením. Její použití fyzicky limitováno velikostí 
studovaných molekul, ale tuto nevýhodu vynahrazuje unikátní možností pracovat s 
dynamickými nebo heterogenními systémy. 
V této disertační práci byla pro detailní strukturní charakterizaci vybraných biologicky 
významných proteinů a jejich komplexů využitá právě NMR poskytující důležité informace o 
jejich biologických rolích. Ve třech různých projektech jsem studovala (i) vztah mezi 
strukturními účinky konkrétních modifikací inzulínového růstového faktoru II (IGF-II) a 
jejich selektivitou k receptorům inzulinové osy, (ii) specifický vazebný mechanismus domény 
SH3 adaptorového proteinu CAS, a (iii) strukturní podstatu vazby fosfatidylinositol 4-kinázy 
beta (PI4KIIIβ) na buněčnou membránu. Pro strukturní studie analogů IGF-II jsem vyvinula 
účinný purifikační protokol, připravila řadu modifikovaných proteinů s upravenou preferencí 
pro příbuzné receptory a strukturně charakterizovala analogy, které vykazovaly výrazně 
sníženou vazbu k inzulínovému receptoru. Získané strukturní informace naznačují, že pro 
specificitu vazby na receptor má klíčovou roli semi-flexibilní C-doména IGF-II. V projektu 
zaměřeném na to, jakým způsobem rozpoznává CAS SH3 doména své ligandy, jsem řešila 
struktury volné CAS SH3 domény a domény v komplexu se dvěma motivy polyprolinových 
peptidů odvozených od tyrosin fosfatázy PTP-PEST nebo od cytoskeletálního proteinu 
Vinculin. Strukturální data ukázala podrobnosti vazebného mechanismu CAS SH3, naznačila, 
že vazba ligandu CAS SH3 je negativně regulována fosforylací zprostředkovanou Src a vedla 
k identifikaci dvou nových buněčných vazebných partnerů CAS. Při hledání rozhodujících 
aspektů v cílení PI4KIIIβ na membránu jsem určila strukturu komplexu tvořeného N-
terminální oblastí PI4KIIIβ kinázy a PolyQ doménou ACBD3. Struktura odhalila podrobný 
mechanismus, na kterém je založena vazba PI4KIIIβ k membráně. 
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1 Introduction 
In this doctoral thesis, nuclear magnetic resonance spectroscopy was used in combination 
with biophysics and protein biochemistry to investigate molecular mechanism of interactions 
of selected protein complexes which are implicated in important biological processes, such as 
cell metabolism and signalling. The first chapter briefly introduces the used technique, its 
principles and current role in the context of structural biology (Chapter 1.1). The following 
sections describe the biological and molecular background of studied systems. In particular, 
insulin, insulin-like growth factor (IGF)-I and IGF-II and their signalling axis and respective 
receptors (Chapter 1.2); the mammalian Crk-associated substrate (CAS) with a focus on its 
key protein-interaction SH3 domain (Chapter 1.3); phosphatidylinositol 4-kinase III beta 
(PI4KIIIβ) and its partner acyl-coenzyme A binding domain containing protein 3 (ACBD3) 
that is essential for the kinase membrane recruitment (Chapter 1.4). 
1.1 Nuclear magnetic resonance 
Together with X-ray crystallography, cryo-electron microscopy or small angle X-ray 
scattering, nuclear magnetic resonance (NMR) is a technique widely used in structural 
biology. It provides valuable information on structure of proteins or nucleic acids, their 
dynamics and interactions.    
First report of using the NMR in structural biology was in 1957 when Martin Saunders 
and co-workers measured the spectrum of ribonuclease [1]. In the mid-1960s, radio 
frequency-pulsed excitation, signal averaging, and Fourier transform data analysis were 
introduced into NMR spectroscopy, which led to dramatic advances in NMR allowing for 
applicability to biological systems [2]. In the beginning of the 1980s, Kurt Wüthrich 
developed methods for studying the three-dimensional structures of proteins by NMR [3] (for 
which he received  the Nobel Prize in chemistry for his contribution to the field of structural 
biology in 2002), which led to annually growing number of deposited structures in Protein 
Data Bank (PDB).  
However, despite great improvements such as multi-dimensional experiments, residual 
dipolar coupling measurements, pulsed field gradients, pulse shaping, high field magnets or 
cryoprobes, the largest source of high resolution protein structures is still X-ray 
crystallography. To this date, there are over 136,000 protein structures in PDB from which 
only 11,000 was obtained by NMR. Nevertheless, this does not suggest NMR to be less 
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important method as this technique has different advantages. Compared to X-ray 
crystallography, NMR experiments are acquired in solution and thus can provide very 
important information on protein dynamics. Protein interactions or protein folding can also be 
studied by NMR. At last, NMR is the only technique to shed light on structural behaviour of 
ubiquitous intrinsically disordered proteins. 
 
This section covers the basic principles of nuclear magnetic resonance spectroscopy 
described by Cavanagh et al in Protein NMR Spectroscopy: Principles and Practice [4].  
The important property of nuclei in NMR is a nuclear spin quantum number (I). A nucleus 
is NMR detectable when 𝐼 ≠ 0. Nuclei important for biological samples that are observed in 
NMR spectroscopy are 
1
H, 
13
C, 
15
N, 
19
F and 
31
P with 𝐼 = 1/2, or 2H with 𝐼 = 1. Nuclei with 
spin quantum number 𝐼 > 0 have a nuclear magnetic moment (𝜇 = 𝛾𝐼) given by the spin of 
unpaired protons and neutrons. In absence of external magnetic field all spins are randomly 
oriented and energy levels are degenerate. For 𝐼 = 1/2, in external magnetic field 𝐵0, the 
nuclear spin is forced to align with (low energy with magnetic quantum number 𝑚 equal to 
1/2) or against (high energy with 𝑚 = −1/2) the direction of 𝐵0. The energy of each level is 
given by 𝐸 = −𝑚ℎ𝛾𝐵0. For 𝑚 ± 1 2⁄ , the energy difference is Δ𝐸 = ℎ𝛾𝐵0. The splitting of 
the degenerate energy level due to the presence of a magnetic field in known as Zeeman 
splitting (Figure 1). The higher the magnetic field 𝐵0, the greater the energy difference Δ𝐸, 
which is resulting in better resolution.  
 
Figure 1 Schematic description of splitting. The difference between two energy states 
is proportional to the magnetic field. The grey spheres represent atomic nuclei which are 
either aligned with (low energy) or against (high energy) the applied magnetic field.  
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The energy difference between the two states corresponds to the energy of the 
electromagnetic radiation that when applied causes the nuclei to change their energy levels. 
For most commonly used NMR spectrometers, 𝐵0 is on the order of Tesla (T) while 𝛾 is in 
the order of 10
5
-10
7
. Consequently, the electromagnetic radiation required is on the order of 
100's of MHz to even GHz. As the energy of a photon is represented by 𝐸 = ℎ𝜈, the 
frequency necessary for absorption to occur is represented as 𝜈 = 𝛾𝐵0 2𝜋⁄  noted Larmor 
frequency, also defined 𝜔 = 𝛾𝐵0 as radial frequency.  
The atom nucleus is surrounded by charged electrons and their orbiting generates a weak 
magnetic field. This local electronic environment around the nucleus slightly changes the 
nuclear magnetic field, which in turn leads to moderate changes in difference between the 
energy levels. This effect is called shielding and is a key feature for structural assignments. 
Nuclei experiencing different magnetic fields due to the local electronic interactions are called 
inequivalent nuclei. Each nucleus requires a different frequency to flip the spin between the 
energy levels, which is represented as a new or additional peak in the NMR spectrum.  
NMR experiment is set of specific radio frequency (RF) pulses and delays that excite the 
nuclei in the studied molecule. The net magnetization 𝑀0 of a sample is aligned with the z-
axis at equilibrium. When a RF pulse is applied along the y-axis (90° pulse); magnetization 
tilts to the x-axis and precesses with a frequency 𝜔 around the z-axis (Figure 2). The 
resonance frequency is detected in the coil. This precession and relaxation back to equilibrium 
are called Free Induction Decay (FID). In order to get an interpretable NMR spectrum, the 
time domain FID is processed using Fourier Transformation (FT) to obtain the frequency 
domain data.  
 
Figure 2 Schematic representation of the basic NMR experiment. By applying the 
radio frequency pulse, the magnetization is transferred to the x-axis where it precesses 
around the z-axis. The relaxation back to equilibrium is detected as a free induction 
decay along the x-axis and Fourier transformed into the frequency domain.  
The resonance frequency of a nucleus is dependent on the strength of magnetic field. To 
eliminate the operating frequency of a spectrometer when describing NMR properties of a 
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nucleus, a chemical shift is defined as 𝛿 = (𝜈 − 𝜈𝑟𝑒𝑓 𝜈𝑟𝑒𝑓⁄ ) × 10
6, with 𝜈𝑟𝑒𝑓 being a 
resonance frequency of a reference molecule, such as sodium trimethylsilylpropanesulfonate 
(DSS) in aqueous solution. The chemical shift is then expressed in parts per million (ppm). 
1.1.1 Nuclear magnetic resonance in structural biology 
Despite the recent boom in application of single particle cryo-electron microscopy, NMR 
spectroscopy and X-ray crystallography still remain the two key experimental methods for 
routine structure determination of biomolecules at high resolution, each with different pros 
and cons in terms of sample preparation, data collection and analysis. In NMR, as in many 
other spectroscopic techniques, we need to know the assignments (frequencies) of the 
particular nuclei in the spectra in order to use them for structural determination or simpler 
task, such as binding site characterization. In order to obtain these frequencies, typically, a set 
of different multidimensional experiments is recoded. A suitable combination of spectra with 
different magnetization transfers allows for assigning all NMR active nuclei in studied 
macromolecule. Low natural abundance of NMR active nuclei in protein samples does not 
allow for effective data acquisition; therefore 
13
C and 
15
N isotope labelling is necessary for 
which bacterial expression is used. 
Resonance assignment  
Commonly, the spectra needed for protein backbone assignment include HN-HSQC, 
CBCA(CO)NH, HNCACB, HNCACO and HNCO. In two-dimensional HN-HSQC 
(heteronuclear single quantum coherence), the magnetization is transferred from proton to 
nitrogen, hence this gives a two dimensional NMR spectrum where all N-H groups, either 
from peptide bonds or from protein side chains, are detected. In three-dimensional 
CBCA(CO)NH and HNCACB, the magnetization transfer continues up to Cα and Cβ, either 
exclusively via the CO group to atoms from a preceding amino acid (CBCA(CO)NH), or to 
both the intraresidual and preceding residue (HNCACB) (Figure 3). A combination of these 
two experiments provides the important information on the particular peptide bond that 
connects two specific amino acids. Resonance frequency of carbonyl atom is obtained in 
HNCACO, giving the frequency of both the intraresidual and the preceding residue, and 
HNCO where only the preceding carbonyl group is detected.  
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Figure 3 Schematic representation of the 3D NMR spectra required for the 
sequence-specific protein backbone resonance assignment. The coloured rectangles 
highlight the detection pathway along the two neighbouring amino acids.  The 
CBCA(CO)NH and HNCO spectra connects signals from the intraresidual amino group 
(i) with the preceding (i-1) carbon atoms. The HNCACB and HN(CA)CO spectra contain 
signals of both, the preceding residue and the intraresidual.  
The backbone assignments provide very reliable information upon the location and 
character of the secondary structure elements (α-helices and β-sheets), the flexibility of the 
backbone over different time scales, or the affinity and binding site of a ligand. In order to 
obtain the full structural characterization of a protein, the side chain resonances need to be 
assigned. For this, a combination of additional 3D experiments is used (Figure 4), some based 
on J-coupling transfer (carbon or hydrogen detected HCCH-TOCSY experiments, 
HBHA(CO)NH, H(CCCO)NNH or CC(CO)NNH) mediated by the electrons participating in 
the bond connecting the nuclei, and some based on nuclear Overhauser effect (
13
C or 
15
N 
edited NOESY) utilizing the transfer of nuclear spin polarization from one population of spin-
active nuclei to another via cross-relaxation.  
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Figure 4 Scheme of detected nuclei in side chain resonance assignment experiments. 
In HCCH-TOCSY experiment, the magnetisation is transferred from the side-chain 
hydrogen nuclei to their attached 
13
C nuclei, which is followed by isotropic 
13
C mixing 
and finally transfer back to the side-chain hydrogen atoms for detection. In 
CBCA(CO)NH and HBHA(CO)NH, the magnetisation pathway starts from the side-
chain hydrogen nuclei, it is transferred to attached 
13
C, then to the carbonyl carbon, to 
the amide nitrogen and finally the amide hydrogen for detection. The chemical shift is 
evolved either on Cα and Cβ carbon atoms or on hydrogen atoms, it is not evolved on 
carbonyl carbon. In CC(CO)NNH and H(CCCO)NNH, the magnetisation is transferred 
from the side-chain hydrogen nuclei to attached 
13
C nuclei. Then isotropic 
13
C mixing is 
used to transfer magnetisation between the carbon nuclei. From here, magnetisation is 
transferred to the carbonyl carbon, on to the amide nitrogen and finally the amide 
hydrogen for detection. 
Structure determination  
NMR structure is typically obtained from multiple input data, such as primary protein 
sequence, dihedral angles of protein backbone (obtained from chemical shifts), orientation 
restrains (derived from residual dipolar coupling [5]), additional covalent bonds (e.g. 
disulphide bonds) and especially the proton distance restrains measured from nuclear 
Overhauser effect spectroscopy (NOESY) experiments. These structural constraints are then 
used for structure calculation of biological macromolecules using a suitable structure 
determination program, such as CYANA (stands for combined assignment and dynamics 
algorithm for NMR applications) [6]. CYANA in particular combines NOESY cross peak 
assignment and structure calculation with a fast torsion angle dynamics algorithm resulting in 
an ensemble of tens of converged structures all satisfying the provided structural constraints.  
The calculation protocol has been standardized to use a completely unfolded protein as an 
initial model that is subsequently minimized against the input NMR data. Using NOESY peak 
lists, protein sequence and assigned protein chemical shifts, CYANA runs seven cycles of 
automated NOE assignment followed by structure calculation [7, 8]. Every iteration is run 
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with original peak lists but using the structure obtained from previous cycle (except for the 
first cycle). The distance restrains for the simulated annealing with the torsion angle dynamics 
algorithm are generated from assigned NOESY cross peaks up to 6 Å. The lowest limit of the 
1
H–1H distance, 1.8 Å, is given as twice the van der Waals radius of 1H atoms. As an output, 
CYANA generates four files. Assignment details about every NOESY peak (cyclen.noa), 
NOE upper distance restraints obtained in cycle n (cyclen.upl), structure bundle obtained in 
cycle n (cyclen.pdb), overview table for the structure calculation in cycle n (cyclen.ovw). 
From the final run, assigned peak lists for each input file are generated (A-cycle7.peaks, 
where A is the name of an input peak list). The final NMR structure is represented by a set of 
typically 10–30 structures with lowest potential energy or number of violations. 
Although there are now set rules for the assignment completeness, the following criteria 
are generally accepted. The assigned chemical shifts of 
1
H, 
13
C and 
15
N signals should be near 
complete (over 90 %) and highly accurate. The total number of unassigned NOE peaks should 
be less than 5 % and they should not be distributed within a certain region of the calculated 
structure. For each residue, there should be more than 10 NOE contacts with a varied intensity 
range and sufficiently high signal-to-noise ratio as well as resolution. 
As CYANA performs the structure calculation with a highly simplified force field using 
smaller van der Waals radii and without static electric potential energy, the obtained model is 
further refined by molecular dynamics calculations with explicit or implicit water model 
systems, such as YASARA [9]. 
An important final step is a structure validation. The accuracy of the refined structures is 
examined based on bond angles, chirality and the side chain rotamer states, as well as the 
backbone conformation by calculation of a Ramachandran plot. In Ramachandran plot 
analysis, the results are classified into four groups: 1) most favoured, 2) additionally allowed, 
3) generously allowed and 4) disallowed. Ideally there are none, or at least less than 10 %, of 
the residues found in the generously allowed and disallowed regions of the Ramachandran 
plot, which means that there are none or only a few geometric issues among the atoms and 
bonds in the structural ensemble. This analysis is mandatory when depositing the molecular 
coordinates into the PDB and can be performed e.g. by PROCHECK-NMR [10]. 
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Molecular interactions 
When a resonance assignment is obtained and a three dimensional structure is solved, 
either from X-ray crystallography or NMR spectroscopy, various molecular processes can be 
studied using a number of NMR approaches.  
A standard method to study molecular interactions is titration of a 
15
N-labelled protein 
with a small molecule ligand or unlabelled protein partner. As the complex is formed, the two 
molecules are in equilibrium between their free and bound states described by the dissociation 
constant Kd. This method is usually based on observation of the 
15
N-
1
H HSQC spectrum of 
one molecule and is called chemical perturbation analysis [11, 12]. Depending on the 
exchange rate of the complex formation and the chemical shift difference between the free 
and bound states up to three exchange regimes can be observed. When the exchange 
frequency between the bound and free forms is fast, in comparison with the chemical shift 
differences between the states, the HSQC correlation peaks move as a function of ligand 
concentration in a continuous manner. In the slow exchange regime, two sets of signals are 
detected for the two states and their integral can be used to monitor their population. For 
analysis, this regime is less convenient than the fast one because the complexed signals need 
to be reassigned again. Analysis of the perturbation gives valuable information about the 
location of the interaction interface. However, it is possible that some residues at the other 
end of the protein may also be slightly perturbed if the global protein fold is affected. The 
intermediate exchange regime gives rise to unfavourable peak broadening, which often 
prevents the signal observation. In some cases, this can be overcome by changing the 
experimental temperature. 
Other approach to facilitate the detailed study of protein interactions by NMR embraces 
the advantages of paramagnetic effects: paramagnetic relaxation enhancements (PRE) and 
pseudocontact shifts (PCS) [13-15]. PRE are detected as resonance line-broadening and are 
predominantly caused by two additional relaxation mechanisms, electron-nucleus dipolar or 
Curie-spin relaxation. The dependence on the distance from the paramagnetic centre is equal 
to 1/𝑟6. On the other hand, PCS alter the resonance frequency. The paramagnetic nuclei 
should be chosen with respect to alterations caused by both, the PRE and the PCS, to induce 
only a moderate line broadening and not wiping out too many signals. Paramagnetic probes or 
tags provide long-range structural restraints, as far as 30 Å. Even though this technique was 
originally developed for structural determination of metalloproteins, several further 
applications were pursued. For instance, paramagnetic tags can be used when the interaction 
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of small molecule gives insufficient spectral differences, or to study the localization of 
independent protein domains. Another valuable relevance is for analyses of the 
conformational space sampled by intrinsically disordered proteins. 
Also, detection of short distances (5–7 Å) utilizing the nuclear Overhauser effect (nOe) 
can be employed to study protein interactions. A mixture of 
13
C-labelled and unlabelled 
interacting partners is used and so called 
13
C-filtered experiments are acquired. The setup of 
this experiment discriminates between intra- and intermolecular contacts thus giving the 
information on atoms involved in direct interaction. This works well for high affinity 
complexes with Kd approximately 50 nM and lower, because when the interacting partners do 
not remain in contact for a longer period of time, less intermolecular nOe’s are detected due to 
line broadening.  
Protein dynamics 
There is no doubt that solving the protein structure is an important goal for understanding 
the molecular level of various biochemical processes. However, biological function of protein 
is not only linked to its three dimensional assembly. If proteins were rigid units, almost no 
interaction would be possible. Certain spatial flexibility is desirable for many interactions 
such as enzymatic activities, protein folding or receptor binding. NMR is an appropriate tool 
to study these structural fluctuations over several different time scales in atomic resolution. 
For pico- to nanosecond time scale, precise information on intrinsic dynamics can be 
obtained from spin relaxation measurements. Except for proline, every peptide group serves 
as a probe along the protein backbone. Both, the 
15
N chemical shift anisotropy the 
15
N-
1
H 
dipolar interaction contribute to the relaxation in the 
15
N-
1
H pair. The information on the 
protein internal motion can be derived from three parameters: longitudinal relaxation rate R1, 
transverse relaxation rate R2, and heteronuclear 
15
N(
1
H) nOe.  
The Carr-Purcell-Meiboom-Gill (CPMG) relaxation dispersion experiments provide 
information on micro- to millisecond molecular motion. The experiment allows to measure 
transverse or spin-spin T2 relaxation times of any nucleus. The pulse sequence for the CPMG 
experiment is based on the spin-echo and consists of a 90º pulse that creates transverse 
magnetization and n times repeated spin-echo period (delay-180º-delay block) that determines 
the decay of the Mxy magnetization. The magnetization that is not refocused during the spin-
echo causes signal broadening. 
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Commonly, acquiring the data under two static magnetic fields is suggested in order to 
reliably estimate the dynamic parameters. Another helpful parameter is given by residual 
dipolar coupling (RDC) measurements. RDC make advantage of chemical shift anisotropy, 
thus reporting on internuclear vector orientations.  
Intrinsically disordered proteins 
Technological advances allow us to look beyond the protein three-dimensional structure, 
such as exploring disordered regions in proteins that were overlooked for many years. A 
substantial part of eukaryotic proteins lacks defined spatial arrangement and yet have a very 
significant biological function [16]. Intrinsically disordered proteins (IDPs) are usually rich 
for repeated sections, so called low complexity regions enriched for Ala, Arg, Gly, Gln, Ser, 
Glu, Lys, and Pro. The absence of rigidity prevents IDPs from crystallization, which makes 
NMR the only high resolution technique to opt for scrutinizing these systems [17].  
When studying IDPs, the overall workflow slightly differs from structured proteins. The 
chemical shifts dispersion of the signals in the amidic region is very poor due to the 
flexibility; however, this property has a favourable acting in signal line-width. To compensate 
for the poor resolution in nitrogen dimension, other directions are being acquired for longer 
time (with of non-uniform sampling method [18]) and also experiments with more than three 
dimensions are implemented [19].  
Although considered generally disordered, IDPs exhibit local structural propensity as well 
as transient long-range contacts. This deviation from random coil state can be very well 
studied using previously mentioned NMR approaches, such as RDC, nOe’s or PRE 
measurements. However, it is important to take into account the fact, that unambiguous 
evaluation of obtained data can be hindered by both ensemble- and time-averaging.  
1.2 Insulin, insulin-like growth factor I, insulin-like growth factor II and 
signalling 
The insulin-IGF axis is a complex signalling pathway mediated by a group of three 
sequentially and structurally homologous peptide hormones, their membrane receptors and 
several circulating IGF-binding proteins. Insulin and insulin-like growth factors (IGF) –I and 
–II are all capable of higher or lower affinity binding towards the transmembrane tyrosine 
kinase receptors insulin receptor isoform A (IR-A), insulin receptor isoform B (IR-B) or 
insulin-like growth factor type I receptor (IGF-1R) [20, 21].  
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All three receptors also share a high degree of homology which is manifested by 
overlapping biological responses upon ligand binding (Figure 5) [22-24]. Binding of insulin 
and IGFs to the receptors triggers two major signalling pathways via autophosphorylation of 
tyrosines within their intracellular tyrosine kinase domains. The first, usually referred to as a 
phosphoinositide 3-kinase (PI3K)/Akt pathway, is key for suppressing the apoptosis thus 
controlling the cell survival. Metabolic effects exerted by this cascade result in protein 
synthesis or a decrease in plasma glucose levels [25]. The second signalling pathway, referred 
to as Ras/ERK, involves activation of the Ras/Raf/MAPK/ERK1/2 cascade, which mediates 
proliferative effects through gene transcription regulation [26].  
Whereas insulin signals mainly via both IR isoforms [27], IGF-I and IGF-II promote the 
mitogenic signalling through IGF-1R [28, 29] and similar mitogenic stimulation results from 
IGF-II binding to IR-A [30].  
 
 
Figure 5 Schematic view of insulin and IGFs binding to corresponding, hybrid and 
non-cognate receptors. Binding interactions with lower affinities are shown in dotted 
lines, regular or high affinities are shown solid. 
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Both IGFs are essential for embryonic development, and are present in serum at 
nanomolar concentrations in adults [31], with IGF-II levels being several-fold higher than 
 IGF-I levels [32]. Whereas the role of IGF-II in tumour development is well documented 
[33], its physiological role in adult remains unclear. It is known that IGF-II is important for 
foetal development and placental function [34, 35] and several animal studies indicate an 
important role for IGF-II in memory enhancement [36-38].  
The availability of IGF ligands for signalling is modulated by a family of high affinity 
IGF-binding proteins 1-6 (IGFBPs 1-6) [39, 40] and insulin-like growth factor type II receptor  
(IGF-2R) [41]. This receptor lacks the tyrosine kinase function and has been shown to clear 
IGF-II from circulation by binding and internalizing the ligand with following subjection to 
lysosomal degradation. The equilibrium of individual components and the appropriate 
function of the entire insulin-IGF system are essential for biological responses such as 
regulation of basal metabolism, cellular growth, proliferation, survival and migration [42]. 
High plasma levels of IGF-II where reported in many malignancies [43] and may 
represent one mechanism by which the tumour stimulates its own growth. Possibly, the 
purpose of the IGF-2R, with no tyrosine kinase domain, may be to counteract excessive IR-A 
and IGF-1R bioactivity by sequestering the overexpressed IGF-II. Recent studies have shown 
a correlation between diabetes treatment and the development of cancer. After many years of 
treating diabetes with insulin analogues, observations in patients indicate that they are both 
effective and safe. However, in some insulin analogues, an increased potential for cancer risk 
has been observed [44-48]. Insulin receptors, responsible for the transfer of both, metabolic 
and mitogenic effects of insulin and IGFs, are usually expressed at high concentrations in 
tumour cells [49, 50]. High expression levels have also been observed for the IGF-1R and its 
ligand in cancer cells [51, 52]. Conversely, some studies have heavily criticized the 
association of insulin analogues and cancer [53, 54]; however, based on the available 
experimental data so far it was neither confirmed nor refused. 
One way of therapeutic intervention in IGF/insulin related diseases is targeting the 
undesirable high concentrations of circulating IGFs via sequestering by IGFBPs. The other 
approach is disruption of ligand binding by receptor antagonist in cancer treatment. For the 
latter, a detailed knowledge of ligand receptor interface is essential and it is addressed in this 
thesis.  
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1.2.1 IGFs  
IGF-I and IGF-II are single chain peptides composed of 70 or 67 amino acids, 
respectively. Mature IGFs consist of four domains: B, C, A and D in order from the N-
terminus cross-linked by three disulphide bonds. IGF-I and -II share over 60% sequence 
identity, mostly in the B and A domains that correspond to the B and A chains in insulin 
(Figure 6).  
The three-dimensional structure of IGF-I was obtained by both NMR and X-ray [55-65] 
whereas the structure of IGF-II has been determined only by NMR [66, 67]. Together with 
insulin, these hormones share the insulin-like conformation consisting of three highly 
conserved α-helices (Figure 5) further stabilized by three characteristic disulphide bonds [59, 
67, 68].  
 
 
Figure 6 The amino acid sequence alignment of insulin, IGF-I and IGF-II illustrates 
their high primary structure homology, with the conserved residues highlighted in dark 
grey and the residues conserved between IGF-I and IGF-II in light grey. The 
organization of IGF-I and IGF-II into B, C, A and D domains is shown below the 
sequences, domains A and B correspond to insulin A and B chain. The positions of 
conserved α-helices are shown as bars above the sequences.  
1.2.2 IR-A, IR-B and IGF-1R 
IR-A, IR-B and IGF-1R are homodimeric and each monomer consists of an extracellular 
(α) and transmembrane (β) subunit, that are linked via four disulphide bonds into a functional 
β-α-α-β homodimer [69-71]. The alternative splicing of IR exon 11 generates a 12-amino-acid 
sequence in the C-terminus of the -subunit or IR-B that is absent in IR-A [72-74]. Each 
monomer contains two insulin/IGF binding sites termed the primary (1) and second (2) site on 
one monomer and 1’ and 2’ on the partner.  
The primary binding site is formed from a leucine rich repeat region (L1) and C-terminal 
helix (-CT region) which combine with the second site of the partner monomer (2’) to form 
the complete binding pocket. The two sites (1 – 2’) bind a single molecule of insulin/IGF 
triggering structural rearrangements and negative cooperativity for binding at the 1’ – 2 site 
[75-77].  
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Figure 7 Domain organization of IGF-1R a IR. A Extracellular part with one site as 
surface and second site as cartoon. B Schematic domain representation. The receptor is 
formed as a heterotetramer by two subunits, α and β, cross linked together via four 
disulphide bridges (in yellow). The α subunit comprises two leucine rich repeat domain 
(L1 and L2), cysteine rich region (CR), fibronectin type III domains (FnIII) and insert 
domain (ID) which in IR-B isoform contains part coded by exon 11 (in dark grey). The β 
subunit is formed by a part of insert domain (ID), fibronectin type III domains (FnIII), 
transmembrane domain (TM), juxtamembrane region (JM), tyrosine-kinase domain (TK) 
and C-terminal domain (CT). 
The mechanisms of insulin or IGF binding to their cognate receptors were originally 
proposed on the basis of extensive mutagenesis studies only [78, 79]. More recently however, 
several reports based on the crystal structures of the insulin:IR [80, 81], ‘activated’ insulin 
analogues [82-84] and the first bound structure of IGF-I through complexation with a IR/IGF-
1R hybrid construct [85] have revealed the binding mode of the hormones at the receptor site 
1 represented by the L1 subunit and -CT segment (Figure 8).  
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Figure 8 Insulin receptor Site 1 interaction On the left, the crystal structure of the 
complex of insulin (red) bound to IR (pdb 4oga)., on the right model with IGF-II (dark 
grey) in the place of insulin. The interaction is carried by domain L1 (grey surface) and 
α -CT peptide (light grey). Aromatic residues involved in binding shown as sticks. 
However, details of the precise arrangement of the C-domain of bound IGF-I or II are still 
unclear but structural rearrangement of this region in conjunction with the -CT region have 
been proposed to be necessary to prevent unfavourable steric clashes (Figure 8). 
Moreover, the C-domain is a region with major differences between IGFs, both in the 
amino acid composition and its length (Figure 6), probably being a key determinant of 
receptor binding specificity, yet due to its dynamic behaviour undetectable in crystal 
structures. 
 
Figure 9 Close-up of CryoEM density with insulin (blue) and α-CT helix (orange) 
fitted. Domains L1 (light green), L2 (green) and α-CT peptide form site 1, the FnIII-1’ 
(yellow) domain represents site 2. The figure was published by Scapin et al. Nature. 
2018 [86]. 
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As the receptor Site 1 has been well defined either from mutagenesis studies or from 
crystal structures, the binding occurring at Site 2 remains to be understood. The fibronectin 
domains FnIII-1 and FnIII-2 are believed to be crucial for this binding. First 4.3 Å resolution 
structure of the insulin receptor ectodomain in the presence of insulin, obtained using single-
particle cryo-electron microscopy (Figure 9), proposed that Site 2 in insulin is represented 
only by residues CysA7, ThrA8 and B-chain residues B4-B10 and by receptor Site 2’ residues 
495-498 and 539-541 in IR FnIII1 domain [86].  
 
Figure 10 Mode of IGF-I binding to IGF-1RΔβ. Left: Bridge formed by IGF-I (black) 
between the site 1 components L1 and αCT΄ and FnIII-2΄, showing separation (asterisk) 
of the L1-CR module away from FnIII-2΄ and IDN΄. Right: Overlay of one “leg” of the 
IGF-1RΔβ homodimer in its IGF-1-bound form (coloured ribbon) onto the corresponding 
domains of the apo IGF-1RΔβ homodimer (white ribbon). Alignment is based on 
domains FnIII-2΄ and FnIII-3΄. Figure was published by Xu et al. Nature 
Communications (2018) [87] 
Another study presenting the crystal structure of IGF-I in complex with IGF-1R 
ectodomain obtained by crystal soaking (Figure 10) [87] confirms similar mode of 
engagement of IGF-I with site 1 as is seen in insulin binding to IR or IGF-I binding to hybrid 
receptor IR/IGF-1R [85, 88, 89]. However it also disputes the significance of FnIII-2 domain 
in Site 2 binding as mutating the key residues forming this contact did not affect the ligand 
affinity. This suggests that residues maintaining the contact of ligand and FnIII-2 domain are 
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only a result of crystal contacts. Nonetheless, to this date there is no clear structural 
information on the binding mode of IGF-II with any of the signalling receptors.  
As the binging interface still remains to be described in detail, the mode of action was 
proposed as a displacement of the receptor monomer units. It was believed that a 
conformational change is required for specific bridging of the receptor's Sites 1 and 2. This 
motion is supposed to initiate the signal transmission to the kinase region. Constraints holding 
transmembrane regions apart are released, and the receptor kinase autophosphorylation is 
triggered [88]. This hypothesis was even corroborated using single-particle cryo-EM of full-
length human IR reconstituted into lipid nanodiscs [90]. Gutmann et al obtained images that 
show how insulin binding to the dimeric receptor converts its ectodomain from an inverted U-
shaped conformation to a T-shaped conformation. It is known, that IR binds insulin with 
negative cooperativity. First ligand binds at physiological concentration with high affinity; 
second ligand can bind at nanomolar concentrations with lower affinity and facilitates 
dissociation of the first. One ligand is sufficient to induce the conversion of the IR 
ectodomain from the U- to the T-shaped conformation [90] 
 
Figure 11 Nanodiscs images and schematic illustration of free and insulin bound IR. 
Illustration of the ligand (insulin, green) binding–induced conformational change in the 
ectodomain and its coupling to the transmembrane domains (TMDs) with concomitant 
activation of the tyrosine kinase domains by autophosphorylation (red asterisks). 
Binding of one ligand molecule is sufficient to induce the transition of the IR 
ectodomain from the inverted U-shaped to the T-shaped conformation. Modified from 
[90]. 
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Despite tremendous effort and progress in scrutinizing both, ligands and receptors, the key 
factors responsible for binding preferences still remain to be found. 
1.3 Crk-associated substrate 
Originally, the Crk-associated substrate (CAS or p130Cas) protein was identified when 
associated with Crk, an adapter molecule or proto-oncogene c-Crk that regulates cell 
adhesion, spreading and migration, and as a protein which is highly phosphorylated on 
tyrosine residues upon transformation by v-Src and v-Crk oncogenes [91, 92]. An oncogene v-
Src was found in Rous sarcoma virus, a type of retrovirus named after an American virologist 
Francis Peyton Rous who was first to propose and later also prove, that cancer could be 
transmitted by a virus [93]. This oncogene encodes a tyrosine kinase that was shown to cause 
a cancer in chickens [94]. Protein v-Crk, identified as an oncogene product of the CT10 
retrovirus, was the first example of an adaptor protein and consists mostly of the Src 
homology 2 (SH2) and Src homology 3 (SH3) domains [95]. 
It is a founding member of the Crk-associated substrate family of adaptor proteins, 
together with HEF1 (human enhancer of filamentation, also known as Cas-L, Crk-associated 
substrate in lymphocyte) [96], EFS (Embryonal Fyn-associated substrate; also known as SIN, 
Src interacting) [97] and CASS4 (CAS scaffolding protein family member 4; also known as 
HEPL, HEF1-Efs-p130Cas-like) [98]. Elevated expression of CAS, also known as BCAR1 
(breast cancer resistance 1), has been linked to poor prognosis in breast cancer [99]. The 
broad variety of the CAS protein family function includes regulation of attachment-dependent 
survival signalling or regulation of cell motility and invasion, control of cell cycle, growth 
factor signalling, cell differentiation, and bacterial and viral infection. The connecting 
attribute of these proteins is the ability to interact with multiple partner proteins. The 
predominant structural feature of all CAS protein family members is their possession of 
numerous protein interaction domains complemented by a number of Src-homology 2-binding 
sites in a ‘substrate domain’, proline-rich motifs or Src-homology 3 domain [100]. 
 
Figure 12 Domain organization of CAS. Src homology (SH3) domain, polyproline 
region (PR), substrate domain (SD), serine rich (SR) domain followed by Src-binding 
region (SB) and the CAS family C-terminal homology domain (CCH). 
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The 870 residues long CAS protein comprises of the several distinct protein domains 
(Figure 12). The N terminus SH3 domain specifically recognizes polyproline sequences in 
many p130Cas binding partners (described in detail in Chapter 4.2.1) and is followed by a 
short proline rich region (PR), a tyrosine rich substrate domain (SD) and a serine rich domain 
(SR) that both can be phosphorylated. Phosphorylation of substrate domains provides a 
binding site for SH2 domain of several adaptor proteins, such as Nck, Crk or SHIPTP2 [101-
103] and the serine rich domain serves for binding of 14-3-3 proteins [104]. The C terminus 
of p130Cas consist of a short Src-binding region (SB) which allows for SH2 or SH3 binding 
of various Src family kinases [105, 106], and the CAS family C-terminal homology domain 
(CCH) providing a site for dimerization or interaction with other CAS proteins [107]. 
1.3.1 SH3 domain  
Src homology 3 (SH3) domains are small modules comprising approximately 60 amino 
acids. They are present in a variety of important proteins, such as protein tyrosine kinases 
(PTKs) of the Src-family, myosin, phospholipase or proteins of signalling pathways 
regulating the cytoskeleton [108]. SH3 domains are found in eukaryotes and viruses, and 
SH3-like domains in prokaryotes [109, 110]. The structure of SH3 domain comprises five to 
eight β-strands arranged into two antiparallel β-sheets or in a β-barrel with the β-strands 
connected by a short 310-helix and loops of different length (Figure 14) [109, 111]. Loops, n-
Src loop, distal loop and RT loop, are responsible for the ligand binding specificity. 
 
Figure 13 Binding of class I and class II ligands to the surface of the SH3 domain. 
On the right is the specificity pocket that typically interacts with an arginine residue.  
Approximate positions of the variable RT and n-Src loops of the SH3 domain are 
denoted. Adapted from [117]. 
The SH3 domains interact with very specific proline rich ligands carrying a pseudo-
symmetrical PxxP motif which adapts polyproline helix type II when bound to an SH3 
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domain. The binding interface can be divided into three discrete pockets. Each of the two 
recognizing one dipeptide unit, while the third pocket binds positively charged flanking 
residues. This amino acid, being arginine or lysine, is also called anchoring residue and is 
important for orienting the ligand with respect to the binding groove on the SH3 domain as 
well as for providing additional binding energy through electrostatic interactions with 
residues in the so-called specificity pocket (Figure 13) [112, 113]. The SH3-binding motifs 
were identified by combinatorial peptide libraries. It was found that proline-rich peptides 
selected by SH3 domains could be classified into two related, yet distinct groups named 
classes I (R/K-x-x-P-x-x-P) and II (P-x-x-P-x-R/K), respectively (Figure 13) [114]. However, 
there are SH3 domains that bind peptides lacking any of these motifs, such as SH3 domains 
from the tyrosine kinase substrate Eps8 and related proteins bind selectively to the PxxDY 
motif [115], the SH3 domains of Fyn (a non-receptor tyrosine-protein kinase playing role in 
many biological processes including regulation of cell growth and survival or cell adhesion) 
and the Fyn-binding protein, engages a site in SKAP55 (Src kinase associated protein of 55 
kDa) bearing a consensus sequence RKxxYxxY that is completely devoid of proline residues 
[116]. 
SH3 domain of CAS interacts with proline motives in various proteins mediating the cell 
signalling. The work described in this thesis helps to understand the molecular mechanism of 
binding and regulation of this interaction.  
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Figure 14 Structural organization of the SH3 domain. The secondary structure 
elements are indicated above the sequence alignment. The structure images were created 
in PyMol using PDB entry 1nyf. The alignment was generated using 
https://toolkit.tuebingen.mpg.de/#/tools/clustalo and Jalview. WebLogo plot of amino 
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acid frequencies of SH3 domains. Frequencies of amino acids were analysed in 
alignments of different human SH3 domains using WebLogo [118]. 
1.4 Phosphatidylinositol 4-kinase beta and Acyl-coenzyme A binding 
domain containing 3 protein 
Upon entering into host cell a virus needs to assemble its viral replication machinery 
(Figure 15). For this, RNA viruses hijack several host membranes, such as the endoplasmic 
reticulum (ER), the Golgi apparatus, the trans-Golgi network (TGN), endosomes, the plasma 
membrane and the mitochondrial outer membrane [119]. The machinery is a supramolecular 
complex of viral RNA-polymerases, host phosphatidylinositol 4-kinases (PI4Ks) and adaptor 
proteins, such as 14-3-3 or Rab11, on the cytosolic leaflet of these membranes. The 
membrane lipid composition plays a critical role in regulating viral RNA synthesis. It was 
shown that a wide variety of different RNA viruses, members of Picornaviridae (poliovirus 
[PV], Coxsackievirus, Aichi virus, enterovirus 71) [120, 121] and Flaviviridae families 
(hepatitis C virus [HCV]) [122, 123], utilize both common and distinct mechanisms to hijack 
host PI4Ks in order to generate essential phosphatidylinositol 4-phosphate (PI4P)-enriched 
replication platforms. They either directly interact with PI4Ks and stimulate kinase activity 
[124] or selectively recruit host PI4Ks to phosphorylate PIs lipids within membranes. For the 
latter can be achieved by the interaction with host Golgi protein Acyl-coenzyme A binding 
domain containing 3 (ACBD3) [121, 125], which is addressed in this thesis.  
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Figure 15 Formation of phosphatidylinositol 4-phosphate (PI4P) lipid-enriched 
viral replication organelles. Upon infection, +RNA viruses hijack host Type III PI4 
kinases and Endoplasmic reticulum (ER), Golgi, and trans-Golgi network (TGN) - into 
so-called replication organelles which subsequently become highly enriched in PI4P and 
cholesterol. PI4P cholesterol-enriched membranes facilitate viral RNA synthesis by 
helping dock and concentrate viral replication proteins; by stimulating viral enzymatic 
reactions; and by generating high curvature membrane pockets that can concentrate and 
segregate viral replication machinery away from the host innate immune defence. 
Adapted from [119] 
1.4.1 Phosphatidylinositol 4-kinase beta 
PI4K enzymes phosphorylate phosphatidylinositol (PI) to generate phosphatidylinositol 4-
phosphate (PI4P). In humans, there are two types of PI4K kinases, each with two members. 
Type II PI4Ks (PI4KIIα and PI4KIIβ) are heavily palmitoylated and thus behave as 
membrane proteins. Type III PI4Ks (PI4KIIIα and PI4KIIIβ, also called PI4Kα and PI4Kβ) 
are soluble cytosolic proteins and must be recruited to the correct membrane type via protein-
protein interactions [126]. PI4P is an essential lipid found in various membrane compartments 
including the Golgi and trans-Golgi network (TGN), the plasma membrane and the endocytic 
compartments. PI4P plays an important role in cell signalling and lipid transport, and serves 
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as a precursor for higher phosphoinositides or as a docking site for clathrin adaptor or lipid 
transfer proteins [127].  
PI4KIIβ is approximately 800 residues long protein. The N-terminal part of the kinase is 
responsible for the interaction with Acyl-coenzyme A binding domain containing protein 3 
(ACBD3), a Golgi resident protein involved in the membrane recruitment. To the C terminus, 
PI4KIIβcontains a helical domain, and kinase domain which can be divided into N- and C-
terminal lobes (Figure 16). 
 
Figure 16 Phosphatidylinositol 4-kinases. Panel A: The domain organization of all four 
phosphatidylinositol 4-kinases. All kinases contain a carboxy-terminal catalytic domain. 
In addition, PI4KIIα contains a Pro-rich at the N terminus; the N-terminal portion of 
PI4KIIIα comprises a long series of armadillo (ARM) repeats, which form an α-solenoid 
loop, helical dimerization domain and another ARM repeat domain; PI4KIIIβ  contains a 
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helical domain and a unique disordered insertion loop within the kinase domain that has 
an unknown function. The domain boundaries are based on published structures. [128-
131]. Panel B: A crystal structure of PI4KIIIβ  with ATP molecule (green) in active site 
(PDB 4wae). The N-lobe of the kinase domain is coloured red, the C-lobe is coloured 
yellow, the helical domain is in light purple. The catalytic site is localized between the 
lobes and is formed mainly by both stretches of antiparallel  β-sheets. 
PI4Kα or PI4Kβ enzymes are hijacked by many of positive-sense single-stranded RNA 
viruses (+RNA viruses), including important human pathogens, to generate specific PI4P-
enriched organelles called membranous webs or replication factories – structures that are 
essential for effective viral replication (Figure 17) [132]. Most +RNA viruses harness 
secretory pathway membranes such as the endoplasmic reticulum, the Golgi apparatus and the 
trans-Golgi network. The replication machinery is assembled on the cytoplasmic leaflet of 
organelle membranes before viral RNA synthesis. It is thought to be effective as the protein 
encountering for the replication process is easier in restricted in two-dimensional space. 
Moreover, forming pockets in membranes can help protect the viral proteins from host innate 
immune system [133].  
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Figure 17 Formation of replication organelles in infected cells Panel A and B show a 
sequence of confocal time-lapse images of a human cell infected with Coxsackievirus B3 
(CVB3). A, the cell expresses FAPP1-PH-GFP, a live-cell PtdIns4P lipid reporter. B, 
immunostained native PI4KIIIβ. Panel C and D show cartoon representation of 
formation of replication organelles. Upon viral infection the Golgi apparatus is being 
resorbed into the ER while new membranes are emerging out of ER exit sites enriched in 
PI4KIIIβ and PI4P lipids. Figure was published in [132]. 
Using cryo-electron microscopy, it was shown that PI4KIIIα together with Eighty five 
requiring protein 3 (EFR3), Tetratricopeptide repeat protein 7 (TTC7), and Family with 
sequence similarity 126 member protein (FAM126) forms a 700-kDa superassembly complex 
at the plasma membrane (Figure 18) [130]. The structure of PI4KIIIα complexed with TTC7 
and FAM126 at a nominal resolution of 3.6 Å revealed that two PI4KIIIα/TTC7/FAM126 
heterotrimers dimerize via their lipid kinase subunits. The N-terminal portion of each kinase 
forms an α-solenoid, a protein fold composed of repeating alpha helix subunits, protruding 
from the opposite face of the complex. This multiprotein complex is recruited to the plasma 
membrane by EFR3. 
 
Figure 18 A schematic model for multiprotein complex – the recruitment of 
PI4KIIIα to the plasma membrane. The PI4KIIIα complex is recruited to the plasma 
membrane by an interaction between TTC7/FAM126 and the unstructured C terminus of 
EFR3. The PI4KIIIα/TTC7/FAM126 complex interacts with the acidic inner leaflet of 
the plasma membrane via a flat, basic surface, orienting its active sites optimally for 
reaction with phosphatidylinositol in the membrane. Scheme was published in [130]. 
Unlike the recruitment of PI4KIIIα to the plasma membrane by several adaptor proteins, 
which is relatively well understood even at the structural level [130, 134, 135], the actual 
molecular mechanism of PI4KIIIβ recruitment to the Golgi is still remains to be understood. 
However, highly specific PI4KIIIβ small molecule inhibitors were developed as potential 
antivirals. In docking analysis, it was shown that 2-alkyloxazole compounds are highly potent 
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and selective inhibitors of PI4KIIIβ via occupation of the adenosine triphosphate (ATP) 
binding site (Figure 16, Panel B) [136]. Forthemore, recent studies even revealed the 
molecular mechanism of the PI4K inhibition in their crystallography data. PI4Ks inhibitors 
compete with the natural binding site for ATP adenine ring, which prevents the binding of 
ATP and inhibits the lipid phosphorylation reaction. This was shown in study focused on 
synthesis of inhibitors with variously modified pyrazolopyrimidine ring as a central core even 
[137] or in study focused on synthesis of compounds bearing a central phenyl ring, 
sulfonamide, and the acetamide moiety all with different substituents [138]. Nevertheless, it is 
still needed to find a balance between PI4K inhibition specificity and host cell cytotoxicity.  
1.4.2 Acyl-coenzyme A binding domain containing protein 3  
Acyl-coenzyme A binding domain containing protein 3 (ACBD3), previously known as 
peripheral-type benzodiazepine receptor and cAMP-dependent protein kinase associated 
protein 7 (PAP7) or Golgi complex-associated protein of 60 kDa (GCP60), is a soluble 
protein of approximately 60 kDa. Several cellular signalling pathways are linked with this 
protein, such as regulation of iron homeostasis, cell apoptosis or neuronal differentiation.  
 
Figure 19 Acyl-coenzyme A binding domain containing protein 3 domain 
organization. ACBD – acyl-CoA-binding domain; CAR – charged amino acids region; 
PolyQ – glutamine-rich region; GOLD – Golgi dynamics domain. 
It is a Golgi protein, one of seven (ACBD1 – ACBD7) that have been identified to bear an 
acyl-coenzyme A binding domain (ACBD) at the N-terminal end [139]. To the C terminus, 
ACBD3 comprises charged amino acids region (CAR), glutamine rich region (PolyQ), and 
Golgi dynamics domain (GOLD). The glutamine rich region is involved in PI4KIIIβ binding 
and the Golgi dynamics domain is important for the Golgi localization. ACBD3 is recruited to 
the Golgi membrane via giantin, a Golgi membrane protein; however, in advanced state of 
viral infection the giantin can be replaced by any of the five non-structural viral proteins: 2B, 
2BC, 2C, 3A, 3AB [121, 140]. 
Comprehensive structural characterization of ACBD3 is hampered by its intrinsically 
disordered parts. Out of four different domains, connected together by flexible linkers, only 
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the GOLD domain of ACBD3 was structurally characterized by X-ray crystallography [140, 
141]. It seems, that viruses use their non-structural proteins as a tool for recruiting PI4K to the 
membrane by docking the ABCD3 GOLD domain (Figure 20) [141]. Moreover, it was shown 
that two groups of picornaviruses, enteroviruses and kobuviruses, have developed similar 
mode of action using their 3A proteins with completely unrelated primary sequences for 
hijacking the same host factor (ACBD3) and its downstream effectors (PI4KIIIβ) (Figure 20) 
[141]. Interaction of ACBD3 with PI4K is mediated by the PolyQ domain [121]. 
 
Figure 20 Putative mechanism of interaction of ACBD3:3A protein complex with 
membrane lipid bilayer. The model is based on molecular dynamics simulation of the 
ACBD3 GOLD domain in and the poliovirus (left) and aichivirus (right) 3A proteins on 
the lipid bilayer. The ACBD3 GOLD domain is shown in cartoon representation with a 
semi-transparent surface and colored in gold except for the membrane binding site, 
which is colored in green. The poliovirus 3A protein is depicted in blue, the aichivirus 
3A protein in red. The model was published in [141]. 
In different proteins, possession of glutamine rich region, also called polyQ domain, may 
have strikingly divergent outcome. It was observed to cause neurodegenerative diseases such 
as Huntington's disease (HD) by formation of insoluble protein aggregates [142]. However, it 
was not clearly determined whether polyQ-mediated proteins aggregation is the cause or the 
consequence of progressive neurodegeneration in polyQ diseases [143]. One proposed 
function in several specific proteins is to serve as a flexible linker between other domains 
[144]. Moreover it was suggested to paly role in protein-protein interactions [145], which is 
also the case in ACBD3 as the PolyQ domain interacts with the PIK4B. 
PolyQ domains are known to be structurally unstable, the whole protein context is 
important for assembling three dimensional fold. The secondary structure in polyQ domain 
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and vicinity is predominantly random coil or helix. However, the regions surrounding the 
polyQ are often not solved in 3D structures due to high degree of flexibility. It is thought, that 
polyQ serves to extend coiled coils at protein termini in highly disordered regions essential 
for protein-protein interactions [146]. 
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2 Aims of the study 
The main objective of this doctoral thesis was detailed structural characterization of 
selected protein complexes using of nuclear magnetic resonance spectroscopy. Obtaining 
high-resolution structural information for these proteins and their complexes proved to be 
instrumental for better understanding the underlying molecular processes.  
 
Specific research aims: 
 
1) Structural characterization of insulin-like growth factor II and its analogues in 
complex with the domain 11 of the insulin-like growth factor 1 receptor 
 
2) Detailed structural characterization of the Crk-associated substrate SH3 domain and 
its complexes with interaction partners 
 
3) Structural basis of the complex formation between phosphatidylinositol 4-kinase 
beta and acyl-coenzyme A binding domain containing protein 3  
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3 Methods 
3.1 Sample preparation and data collection 
All data were collected on Bruker Avance II 850 MHz spectrometer equipped with 
15
N/
13
C/
1
H cryoprobe using 350 μL samples of 15N and 13C uniformly labelled proteins in 
Shigemi tubes. The IGF-II protein samples (75-380 M) were dissolved in 50 mM d4-acetic 
acid (pH 3.0), 5% D2O (v/v), 0.01% (w/v) NaN3. Data for IGF-II and analogues bound to a 
high affinity Domain 11 variant of IGF-2R (D11) [147, 148] were acquired from samples of 
200-400 μM IGF-II:D11 complex in acetate buffer (20 mM d4 acetic acid pH 4.2, 5% D2O 
(v/v), 0.01% (w/v) NaN3) at 35°C. In order to confirm the correct fold of IGF-II analogues, 
one-dimensional 
1
H spectra (unlabelled samples) and two-dimensional 
1
H-
15
N HSQC spectra 
were acquired. The 450 μM CAS SH3 and CAS SH3 fusion chimeric protein samples at were 
measured in the 25 mM sodium phosphate buffer, pH 7.5, 100 mM NaCl, 1 mM TCEP, 0.01% 
NaN3, 5% D2O/95% H2O. The ACBD3 Q domain (280 μM) and ACBD3:PI4KIIIβ complex 
(470 μM) samples were prepared in the 25 mM sodium phosphate buffer, pH 6.5, 100 mM 
NaCl, 1 mM TCEP, 0.01% NaN3, 5% D2O/95% H2O. 
In order to determine the structure either of free or complex bound proteins, a series of 
double- and triple-resonance spectra [149, 150] were recorded on 
13
C
 
/
15
N uniformly labelled 
protein samples to determine essentially complete sequence-specific resonance backbone and 
side-chain assignments. Constraints for 
1
H-
1
H distances distance required to calculate the 
structures for all studies systems were derived from 3D 
15
N/
1
H NOESY-HSQC and 
13
C/
1
H 
NOESY-HMQC, which were acquired using a NOE mixing time of 100 ms.  
3.2 Structure determination 
The structures described in this thesis were calculated using the following optimized 
protocol. The family of converged structures was initially calculated using Cyana 2.1 [6]. The 
combined automated NOE assignment and structure determination protocol was used to 
automatically assign the NOE cross peaks identified in NOESY spectra and to produce 
preliminary structures. In addition, backbone torsion angle constraints, generated from 
assigned chemical shifts using the program TALOS+ [151] were included in the calculations. 
Subsequently, five cycles of simulated annealing combined with redundant dihedral angle 
constraints were used to produce sets of converged structures with no significant restraint 
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violations (distance and van der Waals violations < 0.2 Å and dihedral angle constraint 
violation <5°), which were further refined in explicit solvent using the YASARA software 
with the YASARA force field [9]. The structures with the lowest total energy were selected. 
Analysis of the family of structures obtained was carried out using the Protein Structure 
Validation Software suite (www.nesg.org) and Molmol [152]. The statistics for the resulting 
structures are summarized in respective tables (Table 1, p. 58, Table 2, p. 67, Table 3, p. 76). 
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4 Results and discussion 
4.1 Probing Receptor Specificity by Sampling the Conformational Space 
of the Insulin-like Growth Factor II C-domain 
Hexnerová, R., Křížková, K., Fábry, M., Sieglová, I., Kedrová, K., Collinsová, M., 
Ullrichová, P., Srb, P., Williams, C., Crump, M.P., Tošner, Z., Jiráček, J., Veverka, V., 
Žáková, L. Probing Receptor Specificity by Sampling the Conformational Space of the 
Insulin-like Growth Factor II C-domain. J Biol Chem. 291(40), 21234–21245 (2016) 
 
My contribution 
Optimization of expression and purification of Domain 11 (IGF-2R), 
13
C/
15
N-labelled IGF-II, 
13
C/
15
N-labelled [S39_PQ]IGF-II and 
13
C/
15
N-labelled [N29,S39_PQ]IGF-II; NMR sample 
preparation; design of NMR experiments and their acquisition; NMR data processing and 
evaluation; NMR assignment and structure determination; detailed analysis of the structural 
data; manuscript preparation for submission; addressing the relevant reviewers’ comments. 
4.1.1 Background and motivation 
Insulin, insulin like growth factor (IGF) I and II are highly conserved metabolically active 
proteins with divergent physiological roles. Thanks to high homology among hormones, as 
well as within their receptors (insulin receptor isoforms A and B, IGF type 1 receptor), their 
signalling pathways overlap and alongside the metabolic pathway, they can trigger an 
unfavourable mitogenic response causing excessive cell proliferation.  
Therefore, we designed a series of IGF-II analogues, based on the differences between the 
IGF-I and II primary structures, with the aim to find structural elements responsible for 
receptor specificity. To gain an insight into the structural basis of IGF-II binding specificity to 
IR-A and IGF-1R, we generated a series of mutants carrying amino acid substitutions which 
we designed to make IGF-II more IGF-I-like. We obtained receptor binding affinities and the 
analogues with markedly altered affinities were structurally characterized by NMR.  
4.1.2 Recombinant Production of IGF-II 
To study IGF structure, the efficient production of correctly folded IGF-II had to be 
established, to produce a reference molecule as well as a platform for the design and 
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production of new IGF-II analogues. A recombinant IGF-II expression in E. coli as a fusion 
with an N-terminal and cleavable His6-tagged GB1 protein [153, 154] was used to achieve 
this goal providing relatively high yields of IGF-II analogues (0.8-1.8 mg L
-1
 of culture) with 
only a single additional glycine residue cloning artifact at the N-terminus.  
In total six IGF-II analogues were designed to determine the effects of IGF-I motifs 
incorporation into IGF-II. The modifications were: (i) a point mutation at position Ser29 for 
Asn ([N29]-IGF-II), (ii) an insertion of Gly-Ser after Arg34 ([R34_GS]-IGF-II), (iii) an 
insertion of Pro-Gln after Ser39 ([S39_PQ]-IGF-II), (iv) a combination of both insertions 
([R34_GS, S39_PQ]-IGF-II), (v) a combination of Ser29Asn mutation with Pro-Gln insertion 
([N29, S39_PQ]-IGF-II) and (vi) a combination of Ser29Asn mutation with both insertions 
([N29, R34_GS, S39_PQ]-IGF-II). All analogues had comparable RP-HPLC elution profiles 
to that of IGF-II with one major product and several minor peaks. The characterization of 
minor by-products was prevented by their relatively low yields. The presence of the expected 
tertiary structure was further confirmed by one-dimensional 
1
H NMR spectra (Figure 21) and 
each analogue compared well with the native IGF-II profile.  
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Figure 21 1H NMR spectra of IGF-II. The difference between correctly folded (top 
left) and misfolded (top right) IGF-II spectra was used for verification of correct protein 
folding of the IGF-II analogues. In particular, the presence of dispersed aromatic proton 
signals at 6.5 ppm and upfield shifted methyl signals between 0.5 and -0.2 ppm could be 
utilized to fingerprint correctly folded IGF-II. 
 
misfolded IGF-II IGF-II 
[R34_GS]-IGF-II [N29]-IGF-II 
[R34_GS,S39_PQ]-IGF-II 
[N29, R34_GS, S39_PQ]-IGF-II [N29, S39_PQ]-IGF-II 
[S39_PQ]-IGF-II 
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4.1.3 Receptor binding  
The binding affinities of the IGF-II analogues towards human IR-A and IGF-1R together 
with binding affinities of selected analogues to IR-B are summarized in Figure 22. All 
modifications led to a significantly impaired IR-A binding, ranging from 4.2 to 1.1% of the 
insulin affinity when compared to IGF-II (7.9%). 
An insertion of IGF-I-like features, Ser29Asn or Gly-Ser or Pro-Gln alone or a 
combination of Gly-Ser and Pro-Gln, within the IGF-II molecule led rather unexpectedly to a 
moderate decrease of binding potency towards IGF-1R. However, the Pro-Gln insertion 
combined with the Ser29Asn mutation resulted in a significant increase in binding potency to 
18.8% to that of IGF-I in comparison to IGF-II (10.9%). On the other hand, this effect was 
negated when the Ser29Asn mutation was combined with both insertions.  
Both reference molecules, commercial IGF-II and our recombinant IGF-II, show similar 
binding potency for IR-B compared to IGF-I (1.9 and 1.5% of human insulin, respectively, 
approximately 40 nM). The IR-B binding affinity of [N29]-IGF-II dropped to almost a one 
third of the potency obtained for IGF-II (0.6%, 108 nM). As the binding affinity of the [N29]-
IGF-II analogue for IR-B is more than twice weaker (Kd ~ 108 nM) than the affinity of IGF-II 
we did not further pursue testing IR-B affinities, expecting the affinities of other IGF-II 
analogues would be even lower, similar to that of IGF-I (following the trend observed for IR-
A). 
 
Figure 22 Receptor binding affinities. Shown as a bar plot representation of relative 
binding affinities of native hormones and IGF-II analogues for human IR-A (A), IGF-1R 
(B), and IR-B (C). Error bars represent standard deviation. 
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The isolated Ser29Asn mutation in analogue [N29]-IGF-II reduced its relative binding 
affinity almost twice but to a smaller extent than insertions to the IGF-II C-domain. This 
could indicate that C-domain insertions have some structural effects on IGF-II C-domain and 
that these structural effects are more detrimental to IR-A binding than a point mutation 
Ser29Asn but not additive.  
The Pro-Gln insertion in [S39_PQ]-IGF-II showed the most significant drop in IR-A 
affinity from all tested analogues. Interestingly, this observed decrease in IR-A affinity (about 
7-8-fold compared to IGF-II) was greater than the effect of swapping the entire IGF-II C-
domain for IGF-I C-domain (3.7-fold) described in [155]. It seems that the effect of C-domain 
insertions and Ser29Asn mutation on IR-A affinity is not additive. However, the initial plan to 
reduce IR-A affinity of IGF-II was successful as the four analogues with C-domain insertions 
have low IR-A affinity similar to native IGF-I. These data and data of others [155, 156] 
suggest that there are two main factors affecting the binding potency of IGF-II to IR-A. 
Firstly, a longer C-domain may introduce structural restrictions during binding to the insulin 
receptor. This is in agreement with finding that IGF-I analogues with shorter C-domain 
exhibit enhanced binding affinity to IR-A [157 583]. Secondly, specific C-domain amino 
acids (e.g. Pro39 in IGF-I)may affect the structure of the C-domain main chain and therefore 
binding to IR-A.  
The combination of the Pro-Gln insertion with Ser29Asn mutation in [N29, S39_PQ]-
IGF-II led to an analogue exhibiting higher binding affinity to IGF-1R compared to native 
IGF-II (nearly 2-fold). Our data suggests that the IGF-II specificity towards IGF-1R is 
determined by the amino acid composition of the C-domain, rather than its length. In 
particular, the double insert in [R34_GS, S39_PQ]-IGF-II analogue did not improve IGF-1R 
binding in comparison with IGF-II even though these modifications shift the central C-
domain Ser-Arg-Ser residues (Ser35-Arg36-Arg37 in IGF-I that are essential for IGF-1R 
binding) [158-160] to the position similar to that found in IGF-I. It seems that the introduced 
mutations are not sufficient to counterbalance the absence of other important IGF-I 
determinants (e.g. IGF-I Tyr31 [161-163]). However, the almost doubling in IGF-1R binding 
affinity of [N29, S39_PQ]-IGF-II analogue is very interesting and altogether with its 
markedly lowered affinity for IR-A resulted in almost 10-fold enhanced IGF-1R/IR-A binding 
specificity in comparison with IGF-II. 
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4.1.4 Structural characterization of IGF-II analogues by NMR 
spectroscopy 
Undesirable dynamic and aggregation behaviour of IGF-II severely affects the quality of 
NMR spectra of this protein (Figure 23, top left). This would prevent the accurate structural 
determination required for a detailed comparison between the studied analogues. Previously, 
it has been shown that upon binding to an engineered high-affinity Domain 11 (D11) of the 
IGF-2R, the spectral properties of IGF-II improved dramatically [148]. The fact that the 
investigated IGF-II modifications are distributed on the opposing face to the D11 binding 
interface allowed this system to be utilized for structural studies of the B and C-domains 
alterations.  
As expected, the binding of either 
15
N or 
13
C/
15
N labelled IGF-II analogues to unlabelled 
D11 led to a significant line-narrowing of the NMR signals, as illustrated in Figure 23, despite 
the more than a two-fold increase in the total molecular mass of the system. First, we 
determined the structure of the D11-bound unmodified IGF-II that was utilized in the 
structural analysis of IGF-II analogues. As expected, it is highly similar to the previously 
published structure [148] with some regions being more resolved, especially around the sites 
modified in the analogues, reflecting the substantially higher number of experimental 
restraints (1039 versus 764 unambiguous NOE restraints, Table 1 and [148]).  
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Figure 23 Significant narrowing of IGF-II signals in 
1
H/
15
N HSQC spectrum upon 
binding to IGF-2R Domain 11. A spectrum of free 
15
N labelled IGF-II is shown on the 
left panel. Obtained signals do not correspond to the protein mass of 7.5 kDa. The right 
panel illustrates the signal narrowing observed for IGF-II bound to D11. 
In addition, we verified that binding to D11 did not significantly affect the IGF-II C-
domain and C-terminal portion of the B-domain by comparison of assigned 2D 
1
H/
15
N HSQC 
spectra of free and D11 bound [S39_PQ]-IGF-II (Figure 24). Although significant chemical 
shift perturbations (CSPs) were observed over the A-domain and the first seventy five percent 
of the B-domain, the regions containing the mutations showed very small or negligible CSPs.  
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Figure 24 Comparison of IGF-II analogue in free and D11 bound form. Left: An 
overlay of 1H/15N HSQC spectra of free [S39_PQ]-IGF-II (red) and bound to D11 
(black). Right: Values of combined chemical shift changes calculated from the changes 
of backbone amide signal positions. The major differences upon binding to D11 are 
distributed across the D11 binding interface, while the signals of the C-domain backbone 
amides bearing the modifications remain relatively unaffected by the D11 binding.  
We selected two IGF-II analogues with the most pronounced impact on receptor binding 
[S39_PQ]-IGF-II and [N29, S39_PQ]-IGF-II (Figure 22) for NMR structural characterization 
to understand the molecular basis of these modifications. 
Both analogues, [S39_PQ]-IGF-II and [N29, S39_PQ]-IGF-II, preserved their overall 
structural organization with the three highly conserved α-helices further stabilized by three 
disulphide bonds. As expected, the D11 binding interface on the IGF-II analogues was not 
perturbed by the modifications and structural changes were restricted to the modification sites 
(Figure 25). In both analogues, the C-domain insertion led to a significant change in the 
conformational space sampled by this region of the protein compared to unmodified IGF-II 
with the main differences residing between residues 29 and 42.  
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Figure 25 Solution structures of [S39_PQ]IGF-II (orange) and [N29,S39_PQ]IGF-II 
(purple) compared with non-modified IGF-II (grey). A and B show representative 
structures of the Domain 11-bound IGF-II analogues, and C and D show sets of 20 
converged structures bound to D11 (white). The insertion of Pro-Gln in the C-domain 
after position 39 led to a significant structural rearrangement of the semiflexible loop.  
Detailed analysis (Figure 26) revealed that the insertion of Pro-Gln after Ser39 led to 
increased conformational freedom within the C-loops of both analogues that generated a re-
arrangement stabilized by several new packing interactions in the remote part of the C-
domain. In the native IGF-II sequence, Tyr27 points away from the C-loop and forms 
hydrophobic contacts with Ala61, while the C-loop is unrestrained by additional contacts to 
the other parts of IGF-II (Figure 26A). By contrast, the aromatic ring of Tyr27 forms contacts 
to the methyl group of Ala32 in [S39_PQ]-IGF-II (Figure 4B) and also Arg30 and Pro31 in 
[N29, S39_PQ]-IGF-II (Figure 26C). Arg30 is no longer unrestrained in these analogues and 
interacts with the aromatic ring of Tyr61 (Tyr59 in unmodified IGF-II) via a cation- 
interaction. These new hydrophobic contacts lead to the formation of a better defined C-loop 
that bends around the bulky side-chains of Tyr27 and Tyr61 of both C-domain modified 
analogues (Figure 26B,C).  
In comparison with unmodified IGF-II, the extended C-domain in both analogues is 
spatially constrained and bent towards the triad of aromatic residues at the C-terminus of the 
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B-domain (Phe26, Tyr27 and Phe28). Ser29 in IGF-II (Figure 26A) is located at the hinge of 
the semi-flexible loop with no significant contacts to neighbouring residues. The Pro-Gln 
extension in [S39_PQ]-IGF-II led to the repositioning of Ser29 in close proximity to Tyr27, 
although there are no observed NOE contacts between Ser29 protons and Tyr27 or 
surrounding residues. However, the hydroxyl proton from its side-chain may be involved in 
hydrogen-bonds e.g. with the backbone carboxyl groups either from Pro31 (<2.8 Å in half of 
the structures), which is closer in the extended loop, or from Arg42 (<2.8 Å in quarter of the 
structures) at the opposite side of the loop (Figure 27, Figure 26B).  
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Figure 26 Structural impact of the IGF-II modifications. Non-modified IGF-II (A; 
grey) is compared with [S39_PQ]IGF-II (B; orange) and [N29,S39_PQ]IGF-II (C; 
purple), revealing different spatial orientation of highlighted residues. In particular, the 
rearrangement of the C-domain is driven by repositioning of Ala32 toward Tyr27 and 
Arg30 toward Tyr61 (Tyr59 in non-modified IGF-II) supported by additional contacts 
within this area. 
The modification of Ser29 to Asn29 in [N29, S39_PQ]-IGF-II led to a loss of this 
hydrogen bond and a subtle conformational rearrangement of the C-loop backbone. In 
addition, the Asn29 side-chain is pointing out of the C-loop and is fully solvent exposed with 
NOE contacts between the NH2 group from the Asn29 side-chain and H
2
 from Phe28, 
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perhaps further stabilizing the cluster of contacts between the C-domain and aromatic triad 
which in turn might stabilize the additional interactions seen between Tyr27 and Arg30/Pro31 
(Figure 26C) that were not observed for the [S39_PQ]-IGF-II analogue. 
The comparison of D11-bound structures of IGF-II, [S39_PQ]-IGF-II and [N29, 
S39_PQ]-IGF-II revealed that both analogues differ from IGF-II in the orientation and 
structuring of their C-loops (Figure 25, Figure 26). The significant and similar displacement 
of the C-loops in both [S39_PQ]-IGF-II and [N29, S39_PQ]-IGF-II, altogether with their 
more open C-loop conformations, can be attributed to the effect of their PQ inserts. Moreover, 
the C-loop bends back to generate a turn stabilized by contacts between Tyr27 and Ala32 and 
a hydrogen bond between Ser29 and Pro31 or Arg42 in [S39_PQ]-IGF-II. The absence of this 
hydrogen bond due to the Ser29Asn mutation in [N29, S39_PQ]-IGF-II might be 
compensated for by Pro31 packing against Tyr27.  
 
Figure 27 The formation of stabilizing hydrogen bond in [S39_PQ]IGF-II. The 
hydroxyl proton from the Ser29 side chain is stabilizing the C-loop via a hydrogen bond 
to the backbone carboxyl groups either from Pro31 or Arg42. 
A comparable decrease in IR-A binding affinities of [S39_PQ]-IGF-II and [N29, 
S39_PQ]-IGF-II in comparison with IGF-II indicates it is caused mainly by their similarly 
altered C-loop structures and that the Ser29Asn mutation in context of those analogues plays 
rather a minor role which is well tolerated by IR-A. However, introducing the isolated point 
mutation Ser29Asn or Pro-Gln insertion after Ser39 individually did not have an enhancing 
effect on IGF-1R (quite the opposite), their combination led to a strikingly higher binding 
affinity, suggesting a synergistic effect for IGF-1R receptor interaction.  
In the crystal structure of human IGF-I (PDB 1gzr) [60], the equivalent Asn26 side-chain 
is solvent exposed at the interface of the B and C-domains, with the Asn26, presenting a 
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potential polar hotspot. Asn29 in [N29, S39_PQ]-IGF-II is in a similar position but is less 
exposed due to a partial overlap by the rearranged C-loop (Figure 28A). Asn26 is at the C-
terminus of the IGF-I B-domain, which is structurally altered upon binding to IGF-1R or IR 
[85] (Figure 28; IGF-I receptor-bound structures in cyan). Analogous structural events are 
observed upon insulin binding to IR [81, 84] and it can be expected that receptor-driven 
activation of IGF-II is similar.  
 
Figure 28 A superposition of free or hybrid IR/IGF-1R fragment-bound forms of 
IGF-I with [N29,S39_PQ]IGF-II. A, an overlay of the backbone of free human IGF-I 
(Protein Data Bank code 1GZR; in blue) with [N29,S39_PQ]IGF-II (in purple) and IGF-I 
from a complex with the L1 domain from IR and IGF-1R α-CT peptide (Protein Data 
Bank code 4XSS; in cyan). The positions of Asn26 in IGF-I and Asn29 in IGF-II side 
chains are highlighted. B, the crystal structure (Protein Data Bank code 4XSS) of IGF-I 
(in cyan) in a complex with IR L1 domain (in white) and IGF-1R α-CT peptide (in 
green) overlaid with [N29,S39_PQ]IGF-II in purple. 
Our binding data presented here suggest that Asn29 in [N29, S39_PQ]-IGF-II may play a 
significant role in direct interaction with IGF-1R. However, we have found no reports on IGF-
I Asn26 or IGF-II equivalent Ser29 analogues. In Menting’s structure (PDB 4xss), Asn26 is 
the last IGF-I B-domain residue resolved in the complex with the hybrid IGF-IR/IR where it 
has been captured in the binding site formed from the IGF-IR -CT and IR L1 domains 
(Figure 28B) [85]. However, the structure of the complex did not reveal any specific contacts 
between IGF-I Asn26 and IR L1 domain or IGF-IR -CT. Yet it cannot be ruled out that 
Ser29 within the IGF-II molecule (or Asn29 in [N29, S39_PQ]-IGF-II) may be involved in 
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direct contacts to IGF-1R and this hypothesis could be supported by a positive effect of 
Ser29Asn mutation on IGF-1R binding affinity of [N29, S39_PQ]-IGF-II. Hence, Ser29 may 
represent an important site for engineering of the IGF-1R binding specificity in IGF-II 
analogues. 
Table 1 NMR restraints and structural statistics of the final water-refined sets of 
structures of the domain 11 bound IGF-II, [S39_PQ]-IGF-II and [N29, S39_PQ]- 
IGF-II 
 IGF-II [S39_PQ]-IGF-II 
[N29, S39_PQ]- 
IGF-II 
Non-redundant distance and angle 
constrains 
   
Total number of NOE constraints 1039 1116 1395 
Short-range NOEs    
Intra-residue (i = j) 301 315 341 
Sequential (| i - j | = 1) 321 356 406 
Medium-range NOEs (1 < | i - j | < 5) 160 185 281 
Long-range NOEs (| i - j | ≥ 5) 254 257 364 
Torsion angles 46 46 46 
Hydrogen bond restrains - - - 
Total number of restricting constraints 1085 1162 1441 
Total restricting constraints per 
restrained residue 
16.2 16.8 20.9 
Residual constraint violations    
Distance violations per structure    
0.1 – 0.2 Å 5.05 5.85 9 
0.2 – 0.5 Å 2.15 2.3 2.6 
> 0.5 Å 0 0 0 
r.m.s. of distance violation per 
constraint 
0.02 Å 0.02 Å 0.02 Å 
Maximum distance violation 0.45 Å 0.48 Å 0.48 Å 
Dihedral angle violations per structure    
1 – 10 ° 1.3 1.2 1.7 
> 10 ° 0 0 0 
r.m.s. of dihedral violations per 
constraint 
0.68 ° 0.71 ° 0.75 ° 
Maximum dihedral angle violation 5.00 ° 5.00 ° 5.00 ° 
 
Ramachandran plot summary from 
Procheck 
   
 Most favoured regions 94.8% 92.2% 85.9% 
 Additionally allowed regions 5.2% 7.8% 13.8% 
 Generously allowed regions 0.0% 0.0% 0.1% 
 Disallowed regions 0.0% 0.0% 0.1% 
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r.m.s.d. to the mean structure ordered1 
all 
residues 
ordered1 
all 
residues 
ordered1 
all 
residues 
All backbone atoms 0.4 Å 2.9 Å 1.1 Å 2.2 Å 1.0 Å 1.9 Å 
All heavy atoms 1.0 Å 3.6 Å 1.7 Å 2.9 Å 1.4 Å 2.5 Å 
4.1.5 Conclusions 
The comprehensive biochemical and structural analysis of IGF-II analogues was 
facilitated by development of a straightforward protocol for the production of recombinant 
IGF-II with an additional glycine at the N-terminus. In addition, it was shown, that the 
recombinantly produced IGF-II is equipotent with commercial IGF-II in terms of binding 
properties towards IGF-1R, IR-A or IR-B and can serve as a useful platform for the design of 
IGF-II analogues.  
We prepared six IGF-II analogues with IGF-I-like mutations. All these mutants have 
markedly reduced affinity for IR-A, especially those analogues with Pro-Gln insertions in the 
C-domain. Moreover, one of the analogues, [N29, S39_PQ]-IGF-II, shows the enhanced 
binding affinity for IGF-1R in comparison with IGF-II due to the synergistic effect of Pro-Gln 
insertion and Ser29Asn point mutation. Consequently, this analogue has almost 10-fold 
enhanced IGF-1R/IR-A binding selectivity in comparison with IGF-II. Structural 
characterization of selected analogues revealed that the conformational re-arrangement of the 
C-loop induced by insertion of two residues from IGF-I is manifested in the reduced affinity 
for IR-A. A combination of the effect of this insertion with an additional IGF-I like 
substitution, Ser29Asn, driving the additional subtle re-arrangement of the C-loop forms a 
structural basis for the increased binding affinity of [N29, S39_PQ]-IGF-II for IGF-1R.  
To our knowledge, this is a unique example of the determination of 3D structures of IGF-
II analogues with modifications that have impact on receptor binding affinities. In summary, 
this study helped to identify several important structural determinants in IGF-II and IGF-I C- 
and B-domains, which are co-responsible for different binding specificities of these hormones 
for IR-A and IGF-1R. This resulted in a design of IGF-II analogue with markedly enhanced 
IGF-1R binding specificity. Identification of structural determinants in IGFs and insulin that 
are responsible for specific binding to their cognate receptors is important for designing new 
more specific hormone analogues with potential therapeutic applications. 
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4.2 Structural characterization of CAS SH3 domain selectivity and 
regulation reveals new CAS interaction partners 
Gemperle, J., Hexnerová, R., Lepšík, M., Tesina, P., Dibus, M., Novotný, M., Brábek, J., 
Veverka, V., Rosel, D. Structural characterization of CAS SH3 domain selectivity and 
regulation reveals new CAS interaction partners. Sci Rep. 7(1), 8057 (2017) 
 
My contribution 
Optimization of the CAS SH3 expression and purification protocol. Design of NMR 
experiments and their acquisition; NMR data processing and evaluation; NMR assignment 
and structure determination; detailed analysis of the structural data; manuscript preparation  
4.2.1 Background and motivation 
Mammalian Crk-associated substrate (CAS) is a major substrate of Src kinase. It is a 
docking protein with a significant role in invasion and metastasis of cancer cells and often 
serves as an adaptor protein in multiprotein signalling complexes. The CAS SH3 domain 
mediates the interaction of CAS with polyproline motifs of various kinases (FAK, 
PYK2/RAFTK, FRNK), phosphatases (PTP1B, PTP-PEST), and other proteins (C3G, CMS, 
CIZ and Vinculin). Although, the CAS SH3 domain is indispensable for the CAS-mediated 
signalling within the cell, structural aspects of CAS SH3 ligand binding and regulation are not 
well understood. Therefore, we structurally characterized the interaction of CAS SH3 domain 
with two peptide ligands derived from two known CAS SH3 binding partners PTP-PEST and 
Vinculin in order to shed light on the detailed mechanism of ligand recognition. 
4.2.2 Structural characterization of CAS SH3 complexes by NMR 
spectroscopy 
In order to obtain NMR data for structural characterization of the free or ligand-bound 
CAS SH3 domain, we optimized the recombinant expression for preparation of 
15
N/
13
C-
labelled protein. Using the standard triple-resonance experiments, we obtained a 
comprehensive backbone as well as side-chain resonance assignment for the free CAS SH3 
domain that was subsequently used in combination with the high quality 3D 
15
N- and 
13
C-
edited NOESY spectra for structural calculation. The overview of NMR-derived constraints 
and structural statistics for the final set of water refined converged structures are summarized 
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in Table 2. The conformation of the solution structure is highly similar to that obtained by X-
ray (PDB code 1WYX; backbone root mean square deviation (RMSD) of 0.52 Å for residues 
7–65), but unexpectedly and in contrast to the published dimeric X-ray structure, the CAS 
SH3 domain remained monomeric in solution even at a relatively high concentration 
(~1 mM). A more detailed analysis revealed that the crystallographic dimer is stabilized by 
crystal contacts that stimulate the formation of an additional two-stranded β-sheet at the dimer 
interface that is unambiguously absent in solution (Figure 29). 
 
Figure 29 Stabilization of CAS SH3 domain dimer in crystal structure. The 
crystallographic dimer (PDB code 1WYX) is stabilized by the extensive crystal contacts 
that induced the formation of an additional two-stranded beta-sheet at the dimer 
interface. The beta-sheet is held together by a network of four intra-main chain hydrogen 
bonds are highlighted in yellow. 
Next, complexes of CAS SH3 with Vinculin and PTP-PEST derived molecules using 
isotopically labelled recombinant protein and unlabelled synthetic peptides were structurally 
characterized. The Vinculin and PTP-PEST binding peptides were derived from the known 
physiological ligands representing both variants of the binding sequence, with either arginine 
(PTP-PEST) or leucine (Vinculin) at position +5. Although the complete resonance 
assignments for the peptide-bound protein were obtained, the polyproline character of the 
peptides prevented their unambiguous resonance assignment required for the comprehensive 
structural characterization of the complexes.  
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This issue was overcome by designing of the two fusion chimeric proteins that consisted 
of the CAS SH3 domain linked to peptide sequences. These constructs were successfully 
expressed and purified as uniformly 
15
N/
13
C-labelled proteins and used for NMR structural 
characterization of the CAS SH3 domain in complex with peptide ligands containing a high 
number of repetitive prolines. The CAS-Vinculin and CAS-PTP-PEST fusion chimeric 
proteins contained the sequences corresponding to residues 854–870 and 327–343, 
respectively. In both fusion chimeric proteins, the binding peptide was fused to the SH3 
domain through a Gly/Ser-rich linker peptide. This allowed for a high overall percentage of 
assigned resonances (>98%) and complete assignments within the peptide region (Table 2). In 
addition, the spectra of the peptide-bound protein were highly similar to those obtained for 
fusion chimeric proteins, except for a subset of signals from the peptide portion of the fusion 
proteins (Figure 30). The minimal differences in signal positions can be attributed to the 
increased binding affinity between the protein and peptide regions in fusion chimeric proteins 
relatively to the two individual molecules. 
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Figure 30 
15
N/
1
H HSQC spectra of CAS fusion chimeric proteins and CAS with 
bound peptides. Top: the overlay of the free the CAS SH3 domain with bound peptide 
from PTP-PEST (black) and CAS SH3-PTP-PEST fusion chimeric protein (green). 
Bottom: the overlay of the free the CAS SH3 domain with bound peptide from Vinculin 
(black) and CAS SH3-Vinculin chimera (cyan). 
The NMR analysis of the CAS SH3-peptide ligand fusion chimeric proteins allowed for a 
detailed characterization of the binding interface between the CAS SH3 domain and the 
studied peptides (Figure 31A,B). As expected, the binding of the peptides does not induce a 
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major conformational rearrangement in the CAS SH3 domain. The backbone RMSD was 
calculated 0.97 Å for Vinculin and 0.98 Å for PTP-PEST, for residues 7–65. Comparison of 
the free CAS SH3 domain structure and the complex structures revealed a subtle repositioning 
of the RT loop. This allows peptides to maintain contacts with both the RT loop residues (i.e., 
Asn14, Glu17, Glu21, and Asp20) and residues from the core β-sheet (i.e., Asn58 and Trp43) 
(Figure 31C,D, Figure 33).  
 
Figure 31 Solution structures of the CAS SH3 domain bound to PTP-PEST and 
Vinculin. A set of 40 converged structures of CAS SH3 (dark grey) with (A) PTP-PEST- 
(cyan) and (B) Vinculin-derived peptide (green). (C) and (D) A cartoon representation of 
denoted beta-sheets of CAS SH3 showing the orientation of the two bound peptides. For 
better orientation, the linker is not shown.  
Moreover, the changes in positions of Asn14, Glu17, and Glu21 and a subtle repositioning 
of side chain residues situated in the short 310 helix (Val55 and Arg59; Figure 33) were also 
evident from relative chemical shift perturbation analysis (Figure 32) of CAS SH3 induced by 
binding of PTP-PEST or Vinculin peptide.  
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Figure 32 Relative chemical shift perturbations (CSP) of CAS SH3 induced by 
binding of A PTP-PEST peptide and B Vinculin peptide. The values were calculated 
from changes in positions of backbone amide resonances and divided by standard 
deviation. The distribution of induced changes is similar for both peptides, 
corresponding to highly overlapping binding regions derived from the structural data 
obtained for both complexes. 
The bound structures of the peptides differed in their flexibility. For PTP-PEST, the N-
terminal residues Arg338-Leu343 (positions 5–10) were very flexible (Figure 31A), and for 
Vinculin, the flexible part is only between Glu867 and Val870 (positions 7–10) (Figure 31B). 
Structural statistics for the final water-refined sets of structures are shown in Table 2. 
 
Figure 33 Superimposition of the free CAS SH3 domain (grey) and CAS SH3 PTP-
PEST (cyan) and Vinculin (green) fusion chimeric proteins. The beta sheets are in 
grey, the peptide parts of fusion chimeric proteins are not shown. Repositioning of 
selected residues upon peptide binding denoted with an arrow.  
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Figure 34 A detailed view of the CAS SH3 domain with bound peptides. A surface 
representation of CAS SH3 (grey) with (A) PTP-PEST- (cyan) and (B) Vinculin-derived 
peptide (green). The side chains of CAS SH3 residues involved in binding are shown as 
sticks in dark grey. 
It was previously suggested that phosphorylation of Tyr12 in CAS SH3 domain is 
important for peptide binding [165]. Our structural data clarified the importance of tyrosine 
aromatic ring for non-polar interactions with proline or alanine residue at position 332 or 859 
from PTP-PEST or Vinculin peptides. These effects were also probed by molecular dynamics 
and quantum mechanics (QM) of Tyr12 phosphorylation and mutation. The introduction of 
the phosphate group adds a −2 charge to the site, and by formation of a salt bridge with CAS 
SH3 Lys26, it disrupts the native Tyr12 to peptide proline at position 333 or 860 and P332 or 
A859 CH/π interactions. This is corroborated by QM calculations, which show drops in 
interaction energy of 21 kcal.mol−1 for both PTP-PEST and Vinculin complexes with CAS 
SH3 upon modification of Tyr12 to phosphorylated Tyr12. Furthermore, phosphorylated 
Tyr12 weakens or displaces the native salt bridges of Lys26 with the conserved Glu857 for 
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Vinculin and transient Asp330 for PTP-PEST. This stresses out the importance of acidic 
upstream short distance elements to modulate the effect of phosphorylation on ligand binding. 
Table 2 NMR restrains and structural statistics for the final water-refined sets of 
structures of the free CAS SH3 domain, CAS SH3-PTP-PEST and CAS-SH3-
Vinculin complexes. 
 CAS SH3-PTP-PEST CAS-SH3-Vinculin CAS SH3 
Non-redundant distance and angle 
constrains 
   
Total number of NOE constraints 1998 2483 1165 
Short-range NOEs    
Intra-residue (i = j) 426 494 208 
Sequential (| i - j | = 1) 468 585 305 
Medium-range NOEs (1 < | i - j | < 
5) 
183 267 122 
Long-range NOEs (| i - j | ≥ 5) 921 1137 530 
Torsion angles 80 88 100 
Hydrogen bond restrains - - - 
Total number of restricting 
constraints 
2078 2571 1265 
Total restricting constraints per 
restrained residue 
23.9 28.9 17.6 
Residual constraint violations    
Distance violations per structure    
0.1 – 0.2 Å 9.25 8.40 3.45 
0.2 – 0.5 Å 3.65 3.80 2.22 
> 0.5 Å 0 0 0 
r.m.s. of distance violation per 
constraint 
0.02 Å 0.02 Å 0.02 Å 
Maximum distance violation 0.50 Å 0.50 Å 0.50 Å 
Dihedral angle violations per 
structure 
   
1 – 10 ° 1.23 0.9 2.33 
> 10 ° 0 0 0 
r.m.s. of dihedral violations per 
constraint 
0.46 ° 0.31 ° 0.51 ° 
Maximum dihedral angle violation 5.00 ° 4.90 ° 5.00 ° 
Ramachandran plot summary from 
Procheck 
   
 Most favoured regions 92.3% 93.1% 96.4% 
 Additionally allowed regions 7.5% 6.7% 3.6% 
 Generously allowed regions 0.1% 0.1% 0.0% 
 Disallowed regions 0.0% 0.0% 0.0% 
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r.m.s.d. to the mean structure ordered1 
all 
residues 
ordered1 
all 
residues 
ordered1 
all 
residues 
All backbone atoms 0.3 Å 2.7 Å 0.2 Å 2.4 Å 0.3 Å 6.7 Å 
All heavy atoms 0.7 Å 3.0 Å 0.5 Å 2.6 Å 0.9 Å 6.9 Å 
1
 Residues with sum of phi and psi order parameters > 1.8 
4.2.3 Conclusions 
In this work, we used a combination of protein biochemistry, NMR-based structural 
biology and molecular dynamics simulations to obtain the molecular basis for the CAS SH3 
domain ligand specificity and regulation of binding. First, we determined the consensus CAS 
SH3 binding motif using the phage display methodology and structurally characterized the 
CAS SH3 domain in its free form and in complex with the two peptides derived from the 
known CAS binding partners, PTP-PEST- and Vinculin, using NMR spectroscopy. Detailed 
analysis of the structural data revealed the requirement for uncommonly localized lysine 
residue at the central position +2 of the CAS SH3 ligands and additionally two rather 
dissimilar optional residues, leucine and arginine, at the anchoring position +5, a motif 
present in nearly all known CAS SH3 ligands. We also identified a new binding surface on 
the CAS SH3 domain located proximally to the first SH3 binding pocket and described its 
interactions with negatively charged amino acid residues localized N-terminally to the 
polyproline core of CAS SH3 ligands. In addition, we further expanded the knowledge of 
CAS SH3 ligand binding regulation by manipulating tyrosine 12 phosphorylation status 
within the CAS SH3 domain and confirmed the negative role of this phosphorylation on 
ligand binding. Finally, by exploiting the identified binding requirements of the CAS SH3 
domain we performed a proteome-wide search and experimentally verified two novel CAS 
SH3 binding partners DOK7 and GLIS2. Interestingly, both DOK7 and GLIS2 were predicted 
to play a role together with CAS within the same protein-protein interaction and functional 
network 
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4.3 Structural insights and in vitro reconstitution of membrane targeting 
and activation of human PI4KB by the ACBD3 protein 
Klima, M., Toth, D. J., Hexnerova, R., Baumlova, A., Chalupska, D., Tykvart, J., Rezabkova, 
L., Sengupta, N., Man, P., Dubankova, A., Humpolickova, J., Nencka, R., Veverka, V., Balla, 
T., Boura, E. Structural insights and in vitro reconstitution of membrane targeting and 
activation of human PI4KB by the ACBD3 protein. Sci Rep. 6, 23641 (2016) 
 
My contribution 
Design of NMR experiments and their acquisition; NMR data processing and evaluation; 
NMR assignment and structure elucidation; structural analysis and manuscript preparation. 
4.3.1 Background and motivation 
Phosphatidylinositol 4-kinase is an enzyme which phosphorylates phosphatidylinositol 
and thus generates phosphatidylinositol 4-phosphate (PI4P). There are four human 
phosphatidylinositol 4-kinases; type II alfa and beta (PI4KIIα and PI4KIIβ), type III alfa and 
beta (PI4KIIIα and PI4KIIIβ). Unlike type II kinases that are heavily palmitoylated and thus 
behave as membrane proteins, type III are soluble cytosolic proteins and need to be recruited 
to the membrane via protein-protein interactions to convert their lipid substrates. PI4KIIIβ is 
critical for the maintenance of the Golgi and trans Golgi network (TGN) PI4P pools, however, 
the actual targeting mechanism of PI4KIIIβ to the Golgi and TGN membranes is unknown.  
Therefore, we focused on PI4KIIIβ and its interacting partner, Golgi adaptor protein acyl-
coenzyme A binding domain containing protein 3 (ACBD3). The aim of this study was to 
structurally characterize ACBD3:PI4KIIIβ complex and explain the detailed mechanism of 
ACBD3-mediated recruitment of PI4KIIIβ to relevant membranes both in vitro and in vivo. 
4.3.2 Structural characterization of ACBD3:PI4KIIIβ complex by NMR 
spectroscopy 
Both, full length ACBD3 and PI4KIIIβ are hard to crystalize as they contain extensive 
intrinsically disordered regions [166]. The complex was initially characterized by hydrogen-
deuterium exchange mass spectrometry (HDX-MS) to determine well folded parts. However, 
not even significantly truncated constructs that included only the ACBD3 Q domain and the 
N-terminal region of PI4KIIIβ were able to form suitable crystals. Therefore, an isotopically 
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labelled free ACBD3 Q domain (residues 241-308) and isotopically labelled ACBD3 Q 
domain in complex with PI4KIIIβ N-terminal region (residues 1-68) were prepared to use the 
NMR spectroscopy for structural characterization. The samples of the complex consisted of 
an equimolar mixture of two uniformly 
15
N/
13
C labelled molecules as the protein complex 
was prepared by co-expression of both proteins.  
 
Figure 35 The 2D 
15
N/
1
H HSQC spectrum for the free ACBD3 Q-domain (residues 
241-308). The backbone amide group signals are labelled with the respective residue 
numbers. The side-chain amides that could be unambiguously assigned are labelled with 
the residue numbers and ‘sc’ abbreviation. 
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Figure 36 2D 
15
N/
1H HSQC spectrum for the ACBD3 Q domain:PI4KIIIβ N-
terminal region protein complex. Both backbone and side-chain (the ‘sc’ abbreviation) 
amide group signals are labelled with the respective residue numbers. The residue 
numbers for the PI4KIIIβ N-terminal region protein are incremented by a 100. Top: the 
full spectrum, bottom: the highly overlapped central region. 
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First, comprehensive backbone and side-chain resonance assignments for the free ACBD3 
Q domain were obtained using a standard combination of triple-resonance experiments as 
described in chapter 1.1.1 (p. 16). The extent of the obtained assignment is illustrated in the 
2D 
15
N/
1
H HSQC spectra (Figure 35). Analogously, we obtained backbone and side-chain 
assignments for the ACBD3241-308:PI4KIIIβ1-68 protein complex (Figure 36). 
Backbone amide signals (
15
N and 
1
H) for the free ACBD3 Q domain (residues 241-308) 
were nearly completely assigned apart from the first four N-terminal residues (Met1-Lys4) 
and Gln44. Over 93% of non-exchangeable side-chain signals were assigned for the free 
ACBD3 Q domain. Alongside the resonance from the four N-terminal residues, the side-chain 
assignments were missing for Gln25 (H

), Gln40 (H

/H

/H

), Gln44 (H

/H

/H

) and Gln48 
(H

) mainly due to extensive overlaps within the spectral regions populated by highly 
abundant glutamine side-chain resonances. Interestingly, the protein complex yielded 
relatively well resolved spectra as illustrated in Figure 36. The assignment of backbone amide 
signals was missing only for two N-terminal residues, Gln2 (ACBD3241-308) and Ala2 
(PI4KIIIβ1-68). The good resolution of the spectra was reflected in an unusually high 
completeness (> 90%) of resonance assignments obtained for non-exchangeable side-chain 
signals. The assignments were used in combination with the NOESY data for structural 
refinement of the free ACBD3 Q domain (residues 241-308) as well as the ACBD3241-
308:PI4KIIIβ1-68 complex. 
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Figure 37 The overall structure of the free ACBD3 Q domain and in complex with 
the PI4KIIIβ N-terminal region. (A) Superposition of the 30 converged structures 
obtained for the Q domain of ACBD3 protein shows a nest formed by bending of one 
helix over another. (B) Formation of the ACBD3241-308:PI4KIIIβ1-68 complex displaying 
45 converged structures obtained for the complex, with only the folded part of PI4KIIIβ 1-
68 shown. 
The structure of free ACBD3 Q domain forms a two helix hairpin, with the first helix 
sharply bending over the second helix and forming a fold resembling a three helix bundle that 
serves as a nest for PI4KIIIβ (Figure 37A).  
The complex formation showed that PI4KIIIβ fits in this nest with one helix of the N-
terminus formed between residues 44–64. The interaction is mainly of a hydrophobic 
character with only two hydrogen bonds (between ACBD3241-308 Tyr261 and PI4KIIIβ1-68 
His63 and ACBD3241-308 Tyr288 and PI4KIIIβ1-68 Asp44) helping to stabilize the complex 
formation. We noticed that the kinase helix is amphipathic and its hydrophobic surface 
overlaps with the ACBD3241-308 binding surface. Also, the C-terminus of the ACBD3241-308 is 
significantly stabilized in the protein complex (Figure 37B). 
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Figure 38 A detailed view of the ACBD3241-308:PI4KIIIβ1-68 complex. The interaction 
is facilitated by only two hydrogen bonds (ACBD3241-308 Tyr261: PI4KIIIβ1-68 His63 and 
ACBD3241-308 Tyr288: PI4KIIIβ1-68 Asp44), while the hydrophobic surface of the kinase 
helix nests in the ACBD3 Q domain. ACBD3241-308 is shown in magenta and PI4KIIIβ1-68 
in orange. 
The detailed view in Figure 38 reveals that preceding the kinase helix there are three 
ordered residues (Val42, Ile43, and Asp44) that also contribute to the interaction. The 
remaining part of the PI4KIIIβ N-termini, however, is disordered as illustrated in Figure 39. 
Structural statistics for the final water-refined sets of structures together with the summary of 
the NMR-derived constrains used for structural calculation are shown in Table 3. 
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Figure 39 The overall structure of the ACBD3 Q domain in complex with the 
PI4KIIIβ N-terminal region. Superposition of 30 converged structures. While, the N-
terminal helix is well resolved, the rest of the PI4KIIIβ 1-68 portion remains highly 
disordered. PI4KIIIβ is in orange, ACBD3 Q domain in magenta.  
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Table 3 NMR restrains and structural statistics for the final water-refined sets of 
structures of the Q domain and the kinase helix 
 ACBD3241-308:PI4KIIIβ1-68 ACBD3241-308 
Non-redundant distance and angle 
constrains 
  
Total number of NOE constraints 2396 1086 
Short-range NOEs   
Intra-residue (i = j) 605 282 
Sequential (| i - j | = 1) 694 311 
Medium-range NOEs (1 < | i - j | < 5) 656 332 
Long-range NOEs (| i - j | ≥ 5) 441 161 
Torsion angles 158 118 
Hydrogen bond restrains - - 
Total number of restricting 
constraints 
2554 1204 
Total restricting constraints per 
restrained residue 
17.9 18.0 
Residual constraint violations   
Distance violations per structure   
0.1 – 0.2 Å 15.22 12.2 
0.2 – 0.5 Å 7.31 6.23 
> 0.5 Å 0 0 
r.m.s. of distance violation per 
constraint 
0.03 Å 0.04 Å 
Maximum distance violation 0.50 Å 0.50 Å 
Dihedral angle violations per 
structure 
  
1 – 10 ° 2.11 2.10 
> 10 ° 0 0 
r.m.s. of dihedral violations per 
constraint 
0.38 ° 0.41 ° 
Maximum dihedral angle violation 4.90 ° 4.9 ° 
Ramachandran plot summary from 
Procheck 
  
 Most favoured regions 95.1 % 94.3 % 
 Additionally allowed regions 4.9 % 5.5 % 
 Generously allowed regions 0.0 % 0.2 % 
 Disallowed regions 0.0 % 0.0 % 
r.m.s.d. to the mean structure ordered1 all residues ordered2 all residues 
All backbone atoms 0.4 Å 10.9 Å 0.8 Å 1.3 Å 
All heavy atoms 0.8 Å 11.0 Å 1.2 Å 1.8 Å 
1 residues 5A-66A,54B-75B, 2 residues 5A-66A 
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4.3.3 Conclusions 
The membrane recruitment of PI4KIIIβ is essential to ensure its proper function at the 
Golgi and trans Golgi network. The main aim of this work was detailed characterization of the 
molecular mechanism and structural basis for the PI4KIIIβ membrane recruitment. Although 
there were several key candidates that might be key for this process, we focused on ACBD3, 
as it was shown that it directly interacts with PI4KIIIβ, and whose genetic inactivation 
interferes with the Golgi localization of the kinase [167]. 
The experimental data showed that these proteins directly interact with a submicromolar 
affinity and that the interaction is sufficient to recruit PI4KIIIβ to model membranes in vitro 
as well as to the mitochondria where PI4KIIIβ is never naturally found. To understand this 
process at the atomic level we solved the solution structure of ACBD3:PI4KIIIβ minimal 
complex and found that the PI4KIIIβ N-terminal region is highly dynamic and contains only a 
short amphipatic helix (residues 44-64) that binds the ACBD3 Q domain. The highly dynamic 
character of interacting regions from both proteins required using NMR spectroscopy that can 
tolerate the conformational variability of the studied system. The Q domain adopts a helical 
hairpin fold, resembling crossed fingers, that is further stabilized upon binding the kinase 
helix. The NMR structure revealed that prevalent hydrophobic nature of the interaction 
stabilized by a pair of intermolecular hydrogen bonds. 
Presented data strongly suggest that the complex formation does not directly influence the 
kinase catalytic activity but experiments with model membranes revealed that ACBD3 
enhances activity by an indirect recruiting mechanism that increases the local concentration of 
the substrate in the vicinity of the PI4KIIIβ kinase. 
The ACBD3:PI4KIIIβ molecular complex was reported to be an essential host factor for 
many viruses including aggressive human pathogens in the picornaviral family such as 
poliovirus, coxsackievirus B3, and Aichi virus. Our data therefore open a novel route for 
targeting picornaviral replication. 
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5 Summary 
In this doctoral thesis, biomolecular nuclear magnetic resonance spectroscopy was used to 
obtain a detailed insight into molecular mechanism of interactions of selected proteins 
implicated in important biological processes. A common denominator for all three projects 
was the fact that the studied biological systems were to some extent dynamic and resisted the 
conventional crystallographic approach. 
In order to study IGF-II analogues, a straightforward purification protocol for effortless 
and low cost production of recombinant IGF-II was developed. This allowed for incorporation 
of amino acid sequence modification in the hormone to investigate the effects of primary 
sequence composition on IR-A and IGF-1R binding. The detailed structural characterization 
of IGF-II and its analogues that showed markedly reduced binding towards insulin receptor 
then revealed a molecular mechanism of the semi-flexible C-domain contribution to the 
receptor binding specificity.  
The high-resolution NMR structures of CAS SH3 domain with polyproline peptide motifs 
derived from known CAS binders, tyrosine phosphatase PTP-PEST and cytoskeletal protein 
Vinculin, revealed the binding mechanism for the SH3 domain on a molecular level. The 
interaction is maintained by an uncommon centrally localized lysine residue at position +2 in 
both binding peptides supported an additional anchoring residue at position +5 that bear 
different properties (leucine or arginine). The structural data also suggested that the CAS SH3 
ligand binding is negatively regulated by a Src-mediated phosphorylation of Tyr at position 
12 and were instrumental for identification of the two novel as well as highly biologically 
relevant CAS SH3 binding partners, DOK7 and GLIS2. 
The structural characterization of the complex formed between the N-terminal region of 
PI4KIIIβ kinase and PolyQ domain of ACBD3 revealed the molecular mechanism underlying 
the PI4KIIIβ membrane recruitment. The Q domain of ACBD3 is folded into a helical hairpin 
that directly recognizes a short amphipatic helix formed in the otherwise intrinsically 
disordered N-terminal region of PI4KIIIβ using a network of hydrophobic interactions. 
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